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Abstract
Cytochrome P450 1A-Ligand Interactions: Implications for Substrate
Specificity and Inhibitor Susceptibility
Qingbiao Huang
Cytochromes P450 are heme-containing enzymes that are involved in the metabolism
of a variety of clinically important drugs, endogenous and exogenous compounds,
including a number of procarcinogens. P450 1A subfamily has two members: 1A1 and
1A2. P450 1A1 and 1A2 show high sequence identity (>70%), but display different
substrate specificity and inhibitor susceptibility. P450 1A2 is one of the major hepatic
P450s, which metabolizes more than 11% of drugs currently on the market. Thus, we
focused our attention on studies of this particular P450.
The five key active site residues that are different between P450 1A1 and 1A2 have
been proposed to play an important role in determining the substrate binding orientation.
We adopted phenacetin, an important substrate marker for P450 1A2, to investigate this
role. Kinetic studies have shown that the L382V mutant and other mutants containing
the L382V substitution exhibited markedly higher catalytic efficiency than the wild type
enzyme, while other four single mutants displayed much lower activity. Stoichiometry
studies indicated that the higher coupling occurred due to decreased water formation in
the catalytic cycle by L382V and mutants containing the L382V substitution. Docking
and molecular dynamic simulations suggested that the L382V substitution enabled the
oxidation site of phenacetin to move closer to the ferryl oxygen of heme, thereby
promoting phenacetin metabolism.
In order to verify the above mechanism, NMR T1 relaxation measurements were
utilized to estimate the distance between protons of phenacetin and ferryl oxygen of oxoheme of P450 wild type or mutants. The results showed that the time-averaged
orientations of phenacetin in the active site were very similar in P450 1A2 wild type and
mutants. However, the protons at the site of oxidation of phenacetin were closer to the
ferryl oxygen in P450 1A2 L382V and L382V/N312L mutants than P450 1A2 WT, which
is consistent with the findings from molecular modeling.
To extend our studies, we explored the interactions between inhibitors and P450 1A2
WT and mutants. Molecular modeling techniques, including docking and molecular
dynamic simulations, have been extensively used to predict possible inhibitor-enzyme
interactions and describe the docking energy involved. In some cases, for example with
residue Phe226, π-π stacking might play a major role in these interactions. Good
correlations between docking scores and inhibition constants Ki were obtained using
AutoDock program.
The combination of molecular modeling and experimental techniques helped us to
thoroughly investigate the structure-function relationships of P450 1A2. The insight we
gained into the catalytic and inhibition mechanism(s) of this enzyme stresses the
importance of the active site topology for P450 activity and provides important
implications for the rational design of anticancer drugs.
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Chapter 1

Structure-Function Relationships of Cytochromes P450

1

1.1 Cytochromes P450
1.1.1

General

Cytochromes P450 (P450s) are heme-containing monooxygenease enzymes, which
play important roles in the oxidation of endogeneous substrates and the metabolism of
xenobiotics (Guengerich, 1994; Ortiz de Montellano, 2005). P450s are ubiquitous in
biological systems, and more than 400 isoforms have been identified and sequenced from
plants, animals, bacteria and yeast (Nelson et al., 1996). P450s are divided into two
groups based on their requirements for the redox partners: class I P450s, found in
mitochondria, and class II, more abundant and found in endoplasmic reticulum. Class I
P450s require an iron-sulfur protein (ferredoxin) and an FAD-containing NAD(P)H
ferredoxin reductase for catalysis. Class II P450s, the main xenobiotic metabolizing
enzymes in mammals, require FAD/FMN-containing NADPH P450 reductase and (or)
cytochrome b5.
Hepatic P450s are primarily expressed in the liver, whereas extrahepatic P450s are
mainly found in human extrahepatic tissues including intestine, lung, placenta, and
lymphocytes. Any given P450 can metabolize a large number of substrates but at the
same time it can exhibit overlapping substrate specificity with other P450s. P450s are
involved in toxicant biotransformation, carcinogenesis, and drug metabolism, as well as
endogenous compounds such as prostaglandins, biogenic amines, leukotrienes, bile acids,
or vitamin D. P450s-mediated reactions include hydroxylations, epoxidations, O-, S- and
N-dealkylations, and N-oxidations (Rendic and Di Carlo, 1997). In humans, P450s are
involved in the metabolism of about 75% of the drugs on the market and 90% of those
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drugs are oxidized by major hepatic P450s, such as P450 3A4, 2D6, 2C9, 2C19, and 1A2
(Figure 1.1) (Guengerich, 2008).

1.1.2 Structural Features
Despite the fact that various P450s exhibit a wide range of activities, the overall P450
fold is quite conservative. The triangular prism shape of a P450 is predominantly αhelical with the orthogonal bundle architecture according to CATH classification (Orengo
et al. 1997). The F/G segment, which includes F-helix, F/G-loop and G-helix,
perpendicular to the conserved I-helix with the segment housing the heme cofactor, are
typical structural features of cytochromes P450. The F/G segment together with the B/Cloop are some of the most flexible parts of the mammalian P450 structure and form gates
for the likeliest substrate access or product egress paths to/from the active site. The long
I-helix runs over the distal surface of the heme and spans the entire body of the enzyme
(Figure 1.2). A conserved Thr residue in the central part of the I-helix located in the
proximity of the heme cofactor might participate in O2 activation (Poulos et al., 1987).
The F/G loop and the N-terminal part anchor the membrane. The proximal side of the
mammalian P450s, the region encompassing helices B, C, J, J’, K, L, part of the meander
and the heme binding region, is responsible for the interactions with the enzymes’ redox
partners: NADPH-P450 reductase (CPR, which is essential for its catalytic activity) and
cytochrome b5. Another feature unique to the mammalian P450s is two additional helices,
F’ and G’ available between the F and G helices. Although the overall fold is conserved,
the precise orientation of various structural elements and the length of helices and strands
display substantially differences from one P450 to another.
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In general, the most

conserved regions are closest to the heme (active site) and include the proline-rich cluster
(close to the N-terminus), the loop following the A helix, the C and I-helices, the proton
transfer groove, parts of the K-helix (Lisitsa et al., 2003). The major differences among
P450s are observed in the preferred access/egress paths to/from the active site, the degree
of flexibility in the flexible regions, the size of the active site, and the water network
inside the active site (Otyepka et al., 2007).

1.1.3 Catalytic Mechanism
The most common reaction catalyzed by cytochrome P450 is a monooxygenase
reaction. One atom of oxygen is inserted into an organic substrate (RH) and the other
oxygen atom is reduced to water, as shown in the following equation (Poulos et al., 2003):
RH + O2 + 2H+ + 2e– → ROH + H2O
The cytochrome P450 catalytic cycle was first proposed in 1968 (Katagiri et al.,
1968). The intermediate stages of a P450 catalytic cycle leading to substrate (R–H)
hydroxylation are summarized in Figure 1.3. Initially, the binding of a substrate into the
active site of a P450 binding displaces water ligand, which results in a shift in the ferric
heme iron from low-spin (S = 1/2) towards high-spin (S = 5/2). A more positive potential
of the heme iron makes the transfer of an electron favors from the redox partner to reduce
the heme iron to the ferrous state. Ferrous heme iron binds oxygen rapidly to form the
oxy-ferrous intermediate ([FeO2]2+-RH). Delivery of a second electron from the redox
partner reduces the oxy-ferrous intermediate to the peroxy-ferric intermediate
([FeO2H]2+-RH), which has been determined to be the rate-determining step of the
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reaction (Imai et al., 1977).

Protonation produces the ferric hydroperoxo form

(compound 0). A further protonation leads to the breaking of the O-O bond, the water
formation and iron-oxo intermediates ([FeO]3+-RH) (compound I). Compound I attacks
the nearby substrate and form an hydroxylated form of the substrate. The product (R–OH)
then egresses from the active site of the enzyme and water is allowed to rebind to the
ferric iron, which completes the cycle.
Uncoupling of catalytic turnover from substrate oxidation can reduce the efficiency of
the enzyme by diverting the consumption of reducing equivalents towards the production
of active oxygen species and water. It usually occurs in the reaction cycle at three
“branch points”, namely the substrate-bound oxy-ferrous, peroxy-ferric, and iron-oxo
intermediates, yielding superoxide, hydrogen peroxide, and excess water formation,
respectively (Fang et al, 1997). The decay of these intermediate species occurs under
many circumstances, for instance, electron/proton delivery is not timely, or substrate is
inappropriately positioned, or otherwise resistant to oxidative attack.

1.2 Human P450 1A Subfamily
1.2.1 General
P450 1A subfamily consists of two isomers: P450 1A1 and P450 1A2. P450 1A1 is
an extrahepatic enzyme, which is expressed in the liver at very low levels but mainly
expressed in other tissues including intestine, lung, placenta, and lymphocytes (Schweikl
et al., 1993; Paine et al., 1999). In contast, P450 1A2 is one of the major hepatic P450s
constitutively expressed in the human liver. Both enzymes are regulated in part by the
aryl hydrocarbon receptor (AhR) system and known to be induced by a variety of
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chemicals (Kawajiri and Fujii-Kuriyama, 1991; Shimada et al., 2002). P450 1A1 and
1A2 share 72% amino acid sequence identity and the substrate specificities of these two
enzymes often overlap. P450 1A1 is considered to play a minor role in the elimination of
drugs in vivo. In contrast, P450 1A2 metabolizes about 11% of all marketed drugs
(Shimada et al., 1994).

1.2.2 Structural Features of P450 1A2
P450 1A2 (Protein Data Bank: 2HI4) in complex with α-naphthoflavone has been
resolved by X-ray crystallography, with the structural refinement of 1.95Å, which is
shown in Figure 1.4 (Sansen et al., 2007). The crystal structure of the enzyme includes
residues 34-513, with the transmembrane domain (residues 3-26) truncated. The wildtype P450 1A2 structure contains 12 α-helices designed A-L and 4 β-sheets designed 1-4.
Compared with mammalian P450s of known structures, the most conserved regions and
the most divergent regions are very similar, as has been discussed in the section 1.1.2.
Unlike other mammalian P450s, two short segments F’ and G’ in P450 1A2 are 310
helical fragments instead of typical α-helices. In addition, P450 1A2 structure is different
from either P450 3A4 or P450 subfamily 2 with respect to the length and the local
structure of loop regions connecting conserved secondary structure elements due to less
than 40% amino acid sequence identity (Sansen et al., 2007). P450 1A2 also contains an
additional β-sheet (β3’) between helices H and I, as well as a small α-helix (K’’) residing
at the proximal surface. Interestingly, the region connecting helices C and D possesses a
Ser-rich insertion and forms a loop extending into the solvent. Another remarkable
feature of P450 1A2 structure is a disrupted helix F running across the distal surface of
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the active site cavity (Sansen et al., 2007), which is unique as compared to the structures
of P450 2 subfamily presenting an intact helix F in this region (Schoch et al., 2004; Yano
et al., 2005). In the structure of P450 1A2, no α-helical hydrogen-bonding pattern was
observed at Val220 and Lys221, which results in one helical turn in the middle of helix F
to unwind (Sansen et al., 2007). Two water molecules fill the space and water-bridged
contacts between Val220 carbonyl oxygen and Thr223 Oγ, and Lys221 carbonyl oxygen
and His224 amide nitrogen are formed, respectively. The bending of helix F causes the
C-terminal portion of the helix to move toward the core of the protein, which closes down
the active site cavity.
In the structure of P450 1A2-α-naphthoflavone complex, the compact active site is
closed without apparent solvent or substrate access channels. The active site cavity of
P450 1A2 has a medium volume of 375 Å3 (Sansen et al., 2007), which is larger than that
of P450 2A6 (260 Å3) (Yano et al., 2005), but much smaller than that of P450 3A4 and
2C8, with cavity volumes of 1385 Å3 and 1438 Å3, respectively (Schoch et al., 2004;
William et al., 2000). The narrow substrate binding cavity of P450 1A2 is lined by
residues on helices F and I. Helix I bends as it crosses the heme prosthetic group and its
residues form one flat side of the substrate binding cavity adopt a relatively flat
conformation of the peptide backbone, resulting in a remarkable coplanarity through the
Ala317 side chain, the Gly316-Ala317 peptide bond, and the Asp320-Thr321 peptide
bond. The side chain of Phe226 of helix F forms a parallel substrate binding surface on
the other side of the active site cavity. The cavity of P450 1A2 is stabilized by strong
hydrogen-bonding interactions between the side chain of Thr223 on helix F and the side
chain of Asp320 on helix I. Both Thr223 and Asp320 are involved in an extensive
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network of hydrogen-bonded water molecules and side chains, including Tyr189, Val220,
Thr498, and Lys500.

1.2.3 Substrate Specificity and Inhibitor Susceptibility
P450 1A1 and 1A2 display overlapping substrate specificities and it is clear that the
narrow and flat active site cavity of P450 1A can accommodate well with planar
compounds such as α-naphthoflavone and typical P450 1A selective substrates. With
respect to substrate specificity, although both enzymes are able to oxidize similar
compounds, P450 1A1 metabolizes mainly benzo[a]pyrene and polycyclic aromatic
hydrocarbons (PAHs) to their toxic derivatives (Kawajiri et al., 1991), whereas P450 1A2
preferentially oxidizes heterocyclic aromatic amines (Turesky et al., 1998; Gonzalez et al.,
1994). Relatively small changes in the enzyme active site residues can lead to the
alteration of P450 1A specificities. For instance, P450 1A1 shows a clear preference for
7-ethoxyresorufin as a substrate, whileas P450 1A2 oxidizes 7-methoxyresorufin.
Reciprocal mutants P450 1A1 V382L and P450 1A2 L382V mutants reversely altered the
specificity toward alkoxyresorufins when compared to the wild type enzymes (Liu et al.,
2004).
α-naphthoflavone is a potent, competitive inhibitor of P450 1A2 with Ki values of 150 nM (Shimada et al., 1998; Cho et al., 2003). α-naphthoflavone binds to P450 1A2 in a
preferred orientation with the phenyl ring close to the heme iron, which makes it an
inhibitor rather than a substrate for enzyme (Sansen et al., 2007). The crystal structure of
P450 1A2- α-naphthoflavone complex indicated that the distance between Cα of Leu382
and C'3 and C'4 of α-naphthoflavone is 3.9 and 4.1 Å, respectively, which suggests the
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restricted architecture in the active site cavity and explains the preference of P450 1A2
for shorter alkoxyresorufins (Sansen et al., 2007). The unique active site topology of
P450 1A2 demonstrates how P450 1A enzymes have evolved to efficiently catalyze the
oxidation of polycyclic aromatic hydrocarbons.

Surprisingly, α-naphthoflavone was

readily metabolized by P450 1A1 to form α-naphthoflavone-5,6-diol and αnaphthoflavone-5,6-oxide (Bauer et al., 1995). The different preferences of P450 1A1
and 1A2 toward α-naphthoflavone metabolism could be explained by the fact that the site
of limited P450 1A2 oxidation would be at the other end of the molecule relative to the
site of P450 1A1 oxidation (Sansen et al., 2007).

1.3. Ligand-P450 1A Interactions
1.3.1 Substrates
Substrates of P450 1A1 are planar polyaromatic hydrocarbons, which are comprised
of two to four fused aromatic rings.

The selective substrate for P450 1A1 is 7-

ethoxyresorufin, which has four hydrogen bond acceptor atoms. P450 1A1 does not
appear to play an important role in the metabolism of many drugs because of its
extrahepatic locations of expression.

The selective substrates for P450 1A2 are

heterocyclic amines and amides, which are more polar than P450 1A1 substrates.
Despite these differences, many of the substrate and inhibitor probes used to study P450
1A1 and 1A2 are nonspecific in their recognition between the two enzymes. For example,
caffeine has been shown to be a nonspecific in vitro probe for P450 1A2, since P450 1A1
is also able to metabolize this substrate (Tasaneeyakul et al., 1992). Similarly, the
resorufin

substrates,

7-ethoxyresorufin

and
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7-methoxyresorufin

both

undergo

dealkylation by P450 1A1 and P450 1A2, though the efficiencies of the reaction are
different (Nerurkar 1993).
Due to the importance of P450 1A2 in drug metabolism, the substrate probes for this
enzyme have been intensively studied.

Several compounds, including phenacetin,

caffeine and theophylline have been used as substrate probes for P450 1A2 in vivo. The
major reactions that they participate in are phenacetin O-deethylation, caffeine Ndemethylation, and theophylline N-demethylation, respectively.

Among those,

phenacetin O-deethylation reaction is the most important marker reaction for P450 1A2.
Phenacetin undergoes O-deethylation by P450 1A1/1A2 to yield the product
acetaminophen, and it has been used to evaluate the catalytic activity of P450 1A2 in vivo
and in vitro or to investigate its activity and regulation.
Most of the P450 1A2 substrates are hydrophobic with high LogP values, which
indicates that hydrophobic interactions are mainly involved in their binding to P450 1A2
(Lewis et al., 2003). The common features of ligands for P450 1A2 are of one to two
hydrophobic regions, an aromatic ring and a hydrogen bond acceptor (Zhou et al., 2009).
The planar active site architecture in P450 1A2 is well adapted for the oxidation of
relatively large aromatic compounds.

1.3.2 Inhibitors of P450 1A2
1.3.2.1 Mechanism-Based Inhibitors
Mechanism-based inhibitors also called “suicide” inhibitors are transformed by P450s
into reactive species that cause P450s inactivation prior to the release from the active site.
The reactive metabolites which are formed within the active site may cause irreversible
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inhibition through different mechanisms: (a) binding to hydrophobic regions of the active
site, (b) coordination to the heme iron atom, and (c) entering into specific hydrogen
bonding or iron interactions with active site residues (Correia and Ortiz de Montellano,
2004). Mechanism-based inhibitors of P450 1A2 includes several therapeutic drugs such
as carbamazepine, dihydralazine, furafylline, isoniazid, rofecoxib, and zileuton.
Furafylline is a highly selective inhibitor of P450 1A2 in humans and exhibits a potent
inhibitory effect on phenacetin O-deethylase activity, a reaction catalyzed by P450 1A2,
with an IC50 value of 0.07 μM (Sesardic et al., 1990). Interestingly, furafylline does not
inhibit P450 1A1, as accessed by aryl hydrocarbon hydroxylase activity of placental
samples from women who smoked cigarettes (Sesardic et al., 1990).
Drugs behaving as potent mechanism-based inhibitors of P450 1A2 may explain
some drug-drug interactions in patients. For example, when theophylline and the Rwarfarin were co-administrated with a P450 1A2 selective inhibitor rofecoxib, the
concentration of theophylline and the R-warfarin displayed a significant increase since
P450 1A2 was inhibited by rofecoxib (Bachmann et al., 2003; Schwartz et al., 2000).
Administration of furafylline was associated with an elevated plasma levels of caffeine,
due to inhibition of caffeine oxidation, a reaction catalyzed by P450 1A2 (Sesardic et al.,
1990).

1.3.2.2 Competitive and Non-Competitive Inhibitors of P450 1A2
Another class of P450 inhibitors involves competitive and non-competitive inhibitors,
which occupy the active site (competitive) or somewhere else in the enzyme (noncompetitive), making the active site no longer able to accommodate the substrate.
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Typical competitive and non-competitive P450 1A2 inhibitors are relatively small
molecules, usually containing methyl, chloro, or fluoro substitutions such as fluvoxamine,
ANF. Fluvoxamine is a potent selective P450 1A2 inhibitor with IC50 of 0.12-0.30 μM
(Brosen et al., 1993; Rasmussen et al., 1995; von Moltke et al., 1996; Becquemont et al.,
1997). Isosafrole and other selective serotonin reuptake inhibitors such as fluoxetine,
norfluoxetine, and sertraline are also selective inhibitors of P450 1A2, which inhibited
P450 1A2-mediated 7-ethoxyresorufin O-deethylase activity with low Ki values of 0.7,
4.4, 15.9, 8.8, 9.5 and 5.5 μM, respectively (Rasmussen et al., 1995; von Moltke et al.,
1996; Pastrakuljic et al., 1997).
In addition, compounds such as α-naphthoflavone, ellipticine, 7-ethoxycoumarin, 7ethoxyresorufin,

caffeine,

5-

and

8-methoxypsoralen,

nifedipine,

propranolol,

paraxanthine, theophylline, caffeine, 5- and 8-methoxypsoralen, nifedipine, propranolol,
paraxanthine, and theophylline inhibited phenacetin O-deethylation catalyzed by P450
1A1 or 1A2 and displayed high-affinity towards human liver phenacetin O-deethylase. αnaphthoflavone and 7-ethoxycoumarin were approximately 10-fold more potent as
inhibitors of P450 1A2 than 1A1 (Tassaneeyakul et al., 1993).
The effects of flavone and five hydroxylated derivatives on the methoxyresorufin Odemethylase activity catalyzed by P450 1A1 and 1A2 were examined by Zhai et al. (Zhai
et al., 1998). The results showed that flavone displayed higher inhibitory effects on P450
1A2 (IC50 = 0.066 μM) than on P450 1A1 (IC50 = 0.14 μM). Four hydroxylated flavone
derivatives, namely 3-hydroxy-, 5-hydroxy-, 7-hydroxy-, and 3,7-dihydroxyflavone, also
strongly inhibited P450 1A1 (IC50 < 0.1 μM) and P450 1A2 (IC50 < 0.3 μM) (Zhai et al.,
1998).
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1.4 Techniques Used in P450 Studies
1.4.1

Site-Directed Mutagenesis

Site-directed mutagenesis has been widely used for probing the active sites and other
functional regions of P450 enzymes by the substitution of certain amino acid residues,
and it is an important tool in studies of P450 structure-function relationships. Sitedirected mutations of specific amino acids are useful in determining the roles of certain
residues in various processes, such as substrate binding and recognition, the interactions
with redox partners, oxygen binding and its activation, heme binding and membrane
association (Atkins and Sligar, 1989; Johnson, 1992; Lewis, 1998).
Members of P450 1A family have been extensively studied in our lab and many other
laboratories. Sequence alignment of P450 1A1 and 1A2 indicated that residues in five
positions of substrate recognition sequences (SRS) are different from each other (Liu et
al., 2004). Some reciprocal mutations, for example, P450 1A1 S122T, N221T, G225V,
L312N, V382A, and P450 1A2 T124S, T223N, V227G, N312L, L382A, resulted in the
exchange of substrate (alkoxyresorufin) specificity of the enzymes (Liu et al., 2004). In
addition, based on mutagenesis and homology modeling studies of P450 1A2, a series of
residues in the substrate recognition sequence (SRS) regions (for example: Arg108,
Thr124, Thr223, Glu225, Phe226, Lys250, Arg251, Lys253, Asn312, Asp313, Glu318,
Thr319, Asp320, Thr321, Val322, Leu382, Thr385, and Ile386) has been shown to play a
role in P450 1A2-ligand interactions. Residues in the non-SRS regions, such as Lys99,
Arg137, Gln141, Phe186, Phe205, Val227, Lys453, Arg455, and Thr501, also play a role
in P450 1A2-ligand interactions (Zhou et al., 2009).
Site-directed mutagenesis has also been applied to investigate regions where redox
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partners bind with P450s.

A mutation study on P450 2B4 suggested that residues

including the C-helix, the C/D-loop, the K helix and the loop preceding it are responsible
for CPR and cytochrome b6 (Bridges, et al., 1998). Surprisingly, the sites expected to
bind the CPR and cytochrome b6 overlap to a large extent (Clarke et al., 2004).
1.4.2 NMR Studies
One of the most important applications for NMR in P450 studies involves NMR T1
relaxation measurements, which have been employed to estimate substrate-heme
distances for many substrate-P450 pairs: tienilic acid, lauric acid, and diclofenac with
P450 2C9 (Poli-Scaife et al., 1997); codeine and 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine with P450 2D6 (Modi et al., 1996; 1997); cholesterol with P450scc
(Jacobs et al., 1987); acetaminophen with P450s 1A1 and 2B1 (Myers et al., 1994);
caffeine with P450 1A2 (Regal and Nelson, 2000) and laurate and 12-bromolaurate with
P450 BM3 (Modi et al., 1995), as well as flurbiprofen and the effector dapsone with
P450s 2C9 (Hummel et al., 2004), and cooperative binding of acetaminophen and
caffeine with P450 3A4 (Cameron et al., 2007). In addition, solid-state deuterium magic
angle spinning NMR was utilized to study binding of adamantine-d16 to P450 101A1 by
measuring the average distance between the deuteriums and the heme iron (Lee et al.,
1999).
NMR can also provide valuable information on the dynamics of substrate binding to
proteins and the associated conformational changes by observing chemical shifts for
specific residues, which are first isotopically labeled. For examples, 1D and 2D 1H NMR
provided information on the structural features of the binding site of P450 101A1 (Wei et
al., 2005) and P450 2C9 (Poli-Scaife et al., 1997). Camphor binding to P450 101A1
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studied via T1 relaxation measurements combined with 1H–13C HSQC studies of
[13CH3]threonine-labeled P450 101A1 suggested that camphor binds at a peripheral site
at a location near the proposed entry channel (Yao et al., 2007).

1.4.3

Molecular Modeling Techniques

With the availability of crystal structures of P450s, especially major human drugmetabolizing P450s, such as P450 2A6, 2B4, 2C5, 2C8, 2C9, 3A4 and 1A2, various
computational approaches have been utilized to predict the P450s involved in the
metabolism of xenobiotics and the sites of oxidation (de Groot, 2006; Zhou et al., 2006;
Afzelius et al., 2007; Sykes et al., 2008).

Molecular modeling provides a better

understanding on rationalization and prediction of the catalytic activity, ligand specificity,
and regiospecificity of metabolism of P450s. Thus, it is of interest in facilitating the
solution of challenges faced in drug design and is used for high-throughput screening
(HTS) of large number of compounds in the pharmaceutical industries (Isin and
Guengerich, 2008).
Molecular modeling techniques, such as automated docking and molecular dynamics
simulations are used to design site-directed mutagenesis experiments to explore the active
site for amino acid residues determining ligand binding and regiospecificity of
metabolism by P450. Recently, molecular dynamics methods have been conducted to
predict binding constants and to examine changes in activities upon site-directed
mutagenesis in P450 1A1 and 1A2 (Liu et al., 2003; 2004; Tu et al., 2008).
Models capable of predicting the possible involvement of P450s in the metabolism of
drugs are important tools in drug discovery and development. Those models are also
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helpful to predict and identify the potential drug-drug interactions in clinic. The simplest
approach to predicting the activity/binding of a compound is quantitative structureactivity relationships (QSAR) using both experimental and calculated properties.
Pharmacophore modeling, on the other hand, overlays structures of ligands or properties
of ligands in 3D-space in an attempt to describe the physical, spatial and chemical
properties of the active/binding sites. In P450 1A1, pharmacophore models for PAHs
and a variety of small non-PAH substrates were constructed. P450 1A1 active site was
described as a hydrophobic cleft and hydrogen bonding and aromatic interactions were
suggested (Jerina et al., 1982; Kadlubar and Hammons, 1983; Yang, 1988). For P450
1A2, 3D-QSAR methods were used to construct a model for quinolone-type antibacterial
inhibitors (Fuhr et al., 1993), showing four pharmacophore features (two positive and two
negative potentials), as well as for models based on 12 heterocyclic amines, which
suggested positions of likely hydrogen bonding atoms or placement of hydrophobic/bulky
groups (Lozano et al., 2000).
The limited number of crystal structures of P450 led to the development of P450
homology models based on known P450s whose crystal structures have been solved,
assuming that P450s are structural homological. The constructed models have been
successfully utilized to identify or confirmed key residues, evaluate enzyme-substrate
interactions, and explain changes in region- and stereospecificity of substrate oxidation,
as well as alterations in inhibition and activation upon the residue substitution for those
enzymes whose crystal structures have not been determined (Szklarz and Halpert, 1997;
1998; Szklarz et al., 2000).
However, these in silico methods for studying ligand-P450 interactions have had
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limited success in accurately predicting the site(s) of metabolism and the binding
orientation(s) for a particular compound, likely due to the complexity of P450 enzymes,
which show a significant degree of conformational flexibility and wide substrate diversity.
This approach may provide a source of information as a starting point for
biotransformation scientists (Afzelius et al., 2007, Caron et al., 2007) but more
experimental data are required to support and verify the simulation data based on
molecular modeling studies.

1.5 An Overview of Chapters and Research Objectives
The principle objective of our studies was to elucidate the mechanisms involved in
the interactions between P450 1A2 and its substrates/inhibitors. We have chosen a 1A2selective substrate phenacetin and a number of inhibitors with different inhibition
mechanisms, such as competitive and mechanism-based inhibition, to investigate the
substrate specificity and inhibitor susceptibilities of this P450. Five residues located in
the active site that are different between P450 1A1 and 1A2 play a role in determining the
specificity of enzymes, as demonstrated in the case of alkoxyresorufin metabolism (Liu et
al., 2004, Tu et al., 2008). In order to extend our studies, phenacetin was chosen as
another probe substrate to examine the role of these key residues in determining substrate
specificity, catalytic rates, and the binding orientation of phenacetin within the active site.
In addition, P450 1A2 selective inhibitors, as another type of enzyme ligand, have been
included in our studies. The central hypothesis for our studies is that substrate/inhibitor
dynamics in the active site and the interactions between the substrate/inhibitor and the
P450 determine enzyme specificity. A combination of theoretical techniques, such as
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docking and molecular dynamics, and experimental approaches, including site-directed
mutagenesis, NMR and functional analyses, has been utilized to study structure-function
relationships of P450 1A2.
In Chapter 2, we described the enzyme kinetics and stoichiometry results obtained
with P450 1A2 and phenacetin as a substrate, using an approach basically very similar to
that applied previously to study alkoxyresorufin O-dealkylation catalyzed by P450
1A1/1A2 (Liu et al., 2004; Tu et al., 2008). Enzyme kinetic assays demonstrated that
P450 1A2 L382V and multiple mutants containing the L382V substitution displayed
higher catalytic efficiency than P450 1A2 WT, whereas four other single mutants showed
decreased turnover rates. Stoichiometry studies indicated that catalytic activities of P450
1A2 L382V and multiple mutants containing the L382V substitution increased due to less
water formation (lower uncoupling rate). Molecular dynamics simulations suggested that
the mechanism through which the substitution of Leu382 with a small Val promotes
phenacetin oxidation involves the movement of the substrate closer to the oxo-heme,
which assists in the initial hydrogen abstraction.
Chapter 3 describes the results of NMR studies, which have been undertaken to verify
previous modeling outcomes. NMR provides a direct experimental evidence to support
or disprove the ‘distance’ theory proposed by molecular modeling studies. We estimated
and compared the distances between the protons of phenacetin and the ferryl oxygen of
the heme for P450 1A2 WT and mutants using NMR T1 relaxation measurements. The
protons at the oxidation site of phenacetin are closer to the ferryl oxygen of the heme for
P450 1A2 L382V and L382V/N312L mutants than in the case of the WT enzyme.
Binding of inhibitors in the active site of the enzyme is frequently investigated in
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studies of structure-function relationships of P450s.
several inhibitors are presented in Chapter 4.

Our results for P450 1A2 and

Molecular modeling was extensively

utilized to reveal the interactions between various inhibitors and the enzyme. We focused
on the possible interactions and binding energy between the inhibitor and the enzyme.
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Figure 1.1. Proportion of Drugs Metabolized by P450 Enzymes
Adapted from Wrighton and Stevens, 1992 (22):1-21. Although 14 human families of
P450 enzymes have been identified, approximately 95% of all drug oxidation occurs
through the action of six P450 enzymes: P450 1A2, P450 2C8/9, P450 2C19, P450 2D6,
P450 2E1, and P450 3A4/5.
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Figure 1.2. Common Fold of Typical Mammalian P450 2C9 (PDB: 1OG2) with
Labeled Secondary Structure Elements
Adapted from Otyepka et al., 2007 (1770):376-389.
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Figure 1.3. The Catalytic Cycle of Cytochrome P450
The heme depicts as the heme macrocycle, with the oxidation state of the heme iron
indicated. The proximal heme ligand (cysteine thiolate, indicated as an S-atom linked to
the iron) and distal ligand (a water molecule, changing to dioxygen as the cycle
progresses) are also indicated.
Adapted from online http://sites.google.com/site/modelingunibas/P540_cyclus-customsize-644-457.jpg.
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Figure 1.4. The Secondary and Tertiary Structure of Human P450 1A2 (PDB: 2HI4)
The α-helices are in blue and the β-strands are in brown. These secondary structure
elements are designated A–L and 1–4, respectively, and are sequentially identified from
the N terminus. The heme prosthetic group is represented in sticks and is in red. The
substrate binding cavity is illustrated as a red mesh surface.
Adapted from Sansen et al., 2007 (282):14348-14355.
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Chapter 2

Significant Increase in Phenacetin Oxidation on L382V Substitution in
Human Cytochrome P450 1A2

Adapted from Drug Metabolism and Disposition [doi:10.1124/dmd.109.030767 (2010)]
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2.1 Introduction
Cytochromes P450 (P450s) are heme-containing monooxygenase enzymes, which are
involved in the metabolism of numerous exogenous and endogenous compounds. P450s
are ubiquitous in living organisms, with at least 50 families and 82 subfamilies found in
different species. Human P450 1A subfamily has two major isoforms: P450 1A1 and
1A2. P450 1A2, one of the major P450s in the human liver, was first characterized as a
phenacetin O-deethylase (Distlerath et al., 1985). Currently, it is estimated that this
enzyme metabolizes approximately 11% of all drugs in humans (Shimada et al., 1994).
Despite the fact that P450 1A2 participates in the deactivation and detoxification of
xenobiotics, the main interest in this enzyme is because of the metabolic activation of a
large number of chemical carcinogens (Guengerich and Shimada, 1991; Levis et al.,
1994).
In humans, P450 1A2 shares 72% amino acid sequence identity with P450 1A1, but
the substrate specificities and inhibitor susceptibilities of these enzymes are different.
For example, substrates such as phenacetin and 7-methoxyresorufin are primarily
metabolized by P450 1A2 with high catalytic efficiency, whileas P450 1A1 displays weak
capability to oxidize those substrates.

On the other hand, 7-ethoxyresorufin is

preferentially oxidized by P450 1A1 (Nerurkar et al., 1993; Burke et al., 1994). The
structural basis for such functional differences between highly related enzymes can be
investigated using a variety of techniques, including molecular modeling and
experimental methods, such as site-directed mutagenesis and NMR. More recently, the
crystal structure of P450 1A2 was solved by X-ray crystallography (Sansen et al., 2007),
and thus, it provides a practical model for structure-function studies.
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Our previous studies on structure-function relationships of P450 1A1 indicated that
Val382 played an important role in binding of alkoxyresorufin substrates (Liu et al.,
2003). The sequence alignment between P450 1A1 and 1A2 indicated that five active
site residues that are different between these enzymes (Ser122, Asn221, Gly225, Leu312
and Val382 in P450 1A1 and the corresponding residues in P450 1A2: Thr124, Thr223,
Val227, Asn312 and Leu382) might be involved in determining substrate specificity (Liu
et al., 2004). This result was confirmed by the finding that five reciprocal mutations in
P450 1A1 and 1A2 altered enzymatic activity with alkoxyresorufins as substrates.
Moreover, mutations at position 382 in both P450 1A1 and P450 1A2 shifted substrate
specificity from one enzyme to another (Liu et al., 2004). Further computational and
experimental studies with multiple P450 1A2 mutants confirmed the importance of this
residue for alkoxyresorufin oxidation (Tu et al., 2008). Therefore, it would be of interest
to examine the effect of these mutations on oxidation of other types of substrates.
In the current study, we chose phenacetin as a substrate. This compound has been
used as the most common marker for P450 1A2 activity in the in vitro studies of 45% of
new drugs by investigators in the pharmaceutical industry (Yuan et al., 2002). The
objective of the present study was to investigate whether any reciprocal mutations in
P450 1A2 may alter phenacetin oxidation and to examine the potential mechanism(s) that
might be involved. Five single mutants and four multiple mutants containing the L382V
substitution were evaluated using a combination of molecular modeling and experimental
methods.

These included enzyme kinetics and stoichiometry studies, as well as

molecular dynamics (MD) simulations of phenacetin in the active site of P450 1A2
mutants to facilitate the interpretation of experimental results. This study should provide
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an increased understanding of the biochemical aspects of substrate specificity in the P450
family of enzymes.

2.2 Materials and Methods
Materials.

Phenacetin, acetaminophen, 2-hydroxy acetanilide, sodium dithionite,

NADPH, ampicillin, isopropyl-β-D-thiogalactopyranoside (IPTG), δ-aminolevulinic acid,
CHAPS, dilauroyl-L-3-phosphatidyl choline (DLPC) and phenylmethanesulfonyl
fluoride were from Sigma-Aldrich (St. Louis, MO). Nickel-nitrilotriacetic acid agarose
and a gel extraction kit were purchased from QIAGEN (Valencia, CA). Potassium
phosphate, EDTA, acetic acid and high-performance liquid chromatography-grade
methanol were purchased from Thermo Fisher Scientific (Waltham, MA). All the other
chemicals used were of analytical grade and were obtained from standard commercial
sources.

Protein Expression and Purification. The clones of P450 1A1 WT, 1A2 WT and
P450 1A2 single mutants, T124S, T223N, V227G, N312L and L382V, all of them
containing a His-tag for easy purification, were constructed earlier (Liu et al., 2003;2004).
P450 1A2 His-tag multiple mutants, L382V/T223N, L382V/N312L, L382V/T223N/
N312L and L382V/T124S/N312L, were also constructed previously (Tu et al., 2008).
The P450 enzymes were expressed in Escherichia coli DH5α cells and purified
essentially as described previously (Liu et al., 2004; Tu et al., 2008).

During the

purification, the addition of 5 mM caffeine in the purification buffers helped to stabilize
P450 1A2 proteins. The substrate caffeine was removed completely from the enzyme
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preparation during the ultrafiltration stage, as verified by HPLC. Rat P450 reductase was
expressed in E. coli and purified according to an established procedure (Liu et al., 2003).
The final purity of the enzymes was assessed by SDS-polyacrylamide gel electrophoresis.
Western blots were performed using anti-human P450 1A1/1A2 (Oxford Biomedical
Research, Oxford, MI), and P450 proteins were visualized as described previously
(Kedzie et al., 1991). P450 content was determined by reduced CO/reduced difference
spectra (Omura and Sato, 1964), and protein was measured using Folin phenol reagent
(Lowry et al., 1951).

P450 Activity Assay.

Phenacetin O-dealkylase activities of P450 1A2 WT and

mutants were determined by HPLC measurements as described previously (von Moltke et
al., 1996) with some modifications. The reaction mixtures contained 0.5 μM P450 1A2,
1 μM P450 reductase, and 45 μM DLPC in 100 mM potassium phosphate buffer, pH 7.5.
The enzymes and DLPC were preincubated for 2 min at 37°C before the dilution. For
kinetic assays, phenacetin was added at concentrations ranging from 0 to 1000 μM, and
the mixture was incubated for another 3 min at 37°C. The reaction was initiated by
adding NADPH to a final concentration of 1 mM in a total volume of 1 ml, and
conducted for 30 min. The reaction was terminated by the addition of 5 µl of 60% HClO4
and the reaction mixture was put on ice for 10 min. Ten microliters of 2-hydroxy
acetanilide (100 μM) was then added as an internal standard for HPLC determination.
The reaction mixture was centrifuged at 1000g for 5 min, and 100 µl of the supernatant
was removed and used directly for HPLC analysis. The product acetaminophen was
eluted from a C18 column (Alltech Associates, Deerfield, IL) with a mobile phase of
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methanol/0.1% acetic acid (30:70, v/v; flow rate, 1.5 ml/min), and monitored at 254 nm.
The product was quantified using acetaminophen standards. The kinetic parameters
(Vmax and kcat) were calculated using nonlinear regression with GraphPad Software Inc,
(San Diego, CA) Prism software.

Binding Constant Determination. Spectral binding constants for phenacetin bound
in the active site of P450 1A1 WT and P450 1A2 enzymes were obtained using difference
visible spectroscopy (Modi et al., 1995). Solutions (800 µl) contained 0.5 µM P450 1A2
WT or the mutants in 100 mM phosphate buffer, containing 20% glycerol and 0.1 mM
EDTA, pH 7.4. Two microliters of different concentrations of solutions of phenacetin in
menthol was added to the sample cuvette, and the same volume of menthol was added to
the reference, and UV spectra were then recorded. The data were analyzed by nonlinear
regression analysis using Microsoft (Redmond, WA) Excel software.

NADPH

Oxidation.

The

rate

of

NADPH

oxidation

was

spectrophotometrically at 340 nm in a cuvette thermostated at 37°C.

determined
The reaction

mixture was similar to that used for the phenacetin assay and contained 0.5 μM P450
enzyme, 1 μM P450 reductase, 45 μM DLPC and 1 mM phenacetin in a 100 mM
potassium phosphate buffer, pH 7.5, in a volume of 980 µl. The reaction was initiated by
the addition of 20 µl of 50 mM NADPH. The NADPH oxidation rates were recorded for
about 3 minutes at 340 nm from the beginning of the reaction. The molar extinction
coefficient of 6.22 per millimolar per centimeter for NADPH at 340 nm was used to
obtain oxidation rates in nanomole per minute per nanomole of P450. Three 50-µl
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aliquots of the reaction mixture were removed after 1, 2, and 3 min and quenched with 50
µl of 10% CF3COOH.

The triplicate-quenched reaction mixture was then used to

measure hydrogen peroxide (H2O2).

H2O2 Production. The reaction mixtures from the NADPH oxidation assay were
used to measure the production of H2O2 using the xylenol orange iron (III) assay (Jiang et
al., 1990; Fang et al., 1997) with slight modifications. The coloring agent was prepared
by mixing 100 volumes of 125 µM xylenol orange in 100 mM sorbitol and 1 volume of
25 mM of fresh ferrous (Fe2+) ammonium sulphate in 2.5 M H2SO4. The calibration
curve was prepared using the quenched reaction mixture, which was supplemented with
H2O2 at concentrations ranging from 0 to 10 µM. The H2O2 standard solutions were
prepared fresh on the day of the assay by dilution of a 30% H2O2 stock solution. The
reaction mixture was incubated at room temperature for 1 h. Absorbance was recorded
using a Beckman Counter, Inc. (Fullerton, CA) spectrophotometer set at 560 nm to obtain
the concentration of H2O2 produced in nanomole per minute per nanomole of P450.

Oxygen Consumption. The reaction was conducted using a Mitocell (Strathkelvin
Instruments Ltd, Glasgow, U.K.), which was connected to a water bath thermostated at
37°C. The reaction mixture was prepared in a similar way to that for the NADPH
oxidation assay.

Nine hundred eighty microliters of the sample was placed in the

chamber of the Mitocell, and once a steady baseline was established, the reaction was
initiated by the addition of 20 µl of NADPH. The oxygen consumption was recorded
over 5 min as micromolar per hour, which was then converted to nanomole per minute
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per nanomole of P450.

Molecular Modeling Methods: General. Molecular modeling simulations were
conducted using a Silicon Graphics Octane workstation with Insight II software
(Accelrys, San Diego, CA). The crystal structure of P450 1A2 (Protein Data Bank code:
2hi4) was obtained courtesy of Dr. Eric F. Johnson (The Scripps Research Institute, La
Jolla, CA) (Sansen et al., 2007). The heme cofactor was removed and replaced with the
oxoheme cofactor. Substrate phenacetin was constructed with Insight II/Builder module
and optimized. The models of P450 1A2 single and multiple mutants were constructed
from the crystal structure of P450 1A2 WT by the replacement of selected amino acid(s)
and further refinement of the structures according to the previously established procedure
(Liu et al., 2003, 2004; Tu et al., 2008). MD simulations and energy minimization were
carried out using the Insight II/Discover module with the consistent valence force field
supplemented with parameters for heme and ferryl oxygen, as described earlier (Paulsen
and Ornstein, 1991, 1992). The nonbond cutoff was 16 Å, and all the other parameters
were set at their default values. Structural refinement of P450 1A2 WT and mutants
involved 1000 steps of minimization using steepest descent gradient followed by 10-ps
MD and then another 1000 steps of steepest descent minimization.

The optimized

structures were used for the subsequent docking studies.

Docking of Phenacetin into the Active Site of CYP1A2 WT and Mutants. Initially,
phenacetin was manually placed into the active site of P450 1A2 WT and the mutants on
the distal side of the oxoheme. Docking of phenacetin was performed with Insight II
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(Accelrys)/Affinity module using default parameters, as described previously (Liu et al.,
2004; Ericksen and Szklarz, 2005; Tu et al., 2008). Residues within 10 Å of the initial
phenacetin position comprised the flexible region of the receptor (P450 1A2 WT and
mutants) during all the docking runs. The Affinity docking method uses both the Monte
Carlo search technique and simulated annealing approach, followed by the minimization
protocol to generate low-energy substrate binding orientations. A distance-dependent
dielectric constant was applied to simulate charge screening by water molecules. The 10
lowest-energy phenacetin binding orientations obtained from Affinity docking were
selected for further analysis.

MD Simulations of Enzyme-Substrate Complexes. MD simulations were performed
to investigate phenacetin mobility in the active site and the effect of mutations on
substrate orientation.

The starting configuration for MD simulations chosen from

Affinity docking represented the productive binding orientation of phenacetin leading to
its O-dealkylation and had the lowest potential energy rank. The MD simulations of each
phenacetin-enzyme complex were performed at 310 K in vacuo essentially as described
earlier (Liu et al., 2004;Tu et al., 2008). The substrate, heme, and protein residues within
10 Å from the initial substrate position were flexible without any restraints, whereas the
remainder of the protein was fixed. A distance-dependent dielectric constant was used to
simulate aqueous environment, and the nonbond cutoff distance was 16 Å. After 5-ps
MD equilibration phase, the MD simulations were continued for 100 ps, and 400 frames
obtained every 250 fs were extracted to record the snapshots of each enzyme-substrate
complex.
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In addition, to evaluate the effect of explicit solvent on phenacetin dynamics in the
active site, we performed 100-ps MD simulations on solvated enzyme-substrate
complexes using a similar protocol. The enzymes chosen were P450 1A2 WT and the
L382V mutant. The enzyme-substrate complexes were solvated using crystallographic
water molecules from P450 1A2 crystal structure and optimized before MD with 1000
steps of steepest descent minimization using a nonbond cutoff of 16 Å and dielectric
constant of 1. Similar to previous MD simulations, only protein residues, heme, substrate,
and solvent within a 10-Å radius of the initial substrate position were permitted to move,
whereas the remainder of the protein and other water molecules were fixed. This ensures
that none of the moving solvent molecules escape from the vicinity of the active site. In
contrast to previous MD simulations, the flexible region also included 21 water
molecules surrounding phenacetin. For the aqueous simulations, the dielectric constant
was set to 1. All the other parameters were the same as for the previous enzyme-substrate
simulations without explicit solvent present.
All the MD trajectories were examined using Insight II (Accelrys)/Analysis module.
To score the likelihood of hydroxylation, each sampled frame of a given enzymesubstrate complex was evaluated using the following geometric criterion: r ≤ 3.5 Å and θ
≥ 120˚, where r represents the distance between the ferryl oxygen and the hydrogen of the
substrate to be abstracted; θ represents the angle between ferryl oxygen, the hydrogen
atom to be abstracted, and the carbon at the oxidation site, as described previously
(Ericksen and Szklarz, 2005; Tu et al., 2008).

Trajectory data from 100-ps MD

simulations were extracted and graphed using Microsoft Excel. The MD frames where
the geometric criterion, r ≤ 3.5 Å and θ ≥ 120°, was satisfied were counted as hits. The
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number of hits is a useful indicator of whether a P450 1A2-mediated phenacetin Odeethylation occurred.

2.3 Results
Kinetics of Phenacetin O-Deethylation by P450 1A2 WT and Mutants. P450 1A2
enzymes were expressed in E. coli and purified. The overall yield of the procedure was
approximately 20 to 40%, similar to that reported previously (Liu et al., 2004; Tu et al.,
2008). The purity of P450 1A2 WT and mutants verified by SDS-Polyacrylamid gel
electrophoresis and Western blots indicated that they were at least 95% pure. The
spectrum of the FeII-CO complex exhibited a characteristic peak at 450 nm, with little or
no P420 formation. The holoenzyme content of the enzymes was usually in the range of
40 to 60%, as previously observed in our laboratory.
Kinetic parameters, kcat, Km and substrate specificity (kcat/Km), were determined for
purified P450 1A2 WT and mutants using a range of substrate phenacetin concentrations.
Phenacetin undergoes O-deethylation to form acetaminophen as the main product of the
reaction. Kinetic parameters for P450 1A2 WT and mutants are shown in Table 2.1.
Compared with P450 1A2 WT, the mutations affected both kcat and Km. The P450 1A2
L382V mutant and multiple mutants containing the L382V mutation displayed 2- or 3fold higher kcat than the WT enzyme. Four other single mutants, namely, T124S, T223N,
V227G, and N312L, exhibited much lower kcat than the WT.
As shown in Table 2.1, the Km values for P450 1A2 WT and mutants varied greatly.
In general, the Km values for all the mutants were more than 50% lower than for the WT
(~60 μM). The lowest values of Km were observed for several mutants containing the
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L382V substitution, including L382V (~6 μM), L382V/T223N (~8 μM), and
L382V/T124S/N312L (~10 μM), which suggests that the L382V mutation significantly
increased the binding affinity of the enzyme for phenacetin. The substrate specificities of
the L382V mutant and multiple mutants containing the L382V mutation, expressed as
kcat/Km, were at least 5-fold higher than that of the WT (Table 2.1). In particular, the
relative substrate specificities of L382V and L382V/T223N mutants were more than 20fold higher, which is extremely high. Incidentally, phenacetin is less efficiently
metabolized by P450 1A1 WT, (kcat 0.5 min-1 and Km 66 μM), with kcat close to one third
of the value observed with P450 1A2 WT (see Table 2.1) and the kcat/Km ratio lower than
0.01.
Phenacetin binding constants were also determined for P450 1A2 WT and some
mutants. P450 1A2 WT and the N312L mutant showed similar phenacetin binding, with
binding constants of 17.1 μM and 10.2 μM, respectively. In contrast, the L382V and the
L282V/N312L mutants displayed much lower values for binding constants, namely, 0.7
μM and 3.5 μM, indicating tighter substrate binding. P450 1A1 WT exhibited much
weaker binding, with a binding constant of 57 μM.

Stoichiometry of Phenacetin O-Deethylation.

To assess whether the L382V

mutation affected P450 1A2 coupling efficiency of reducing equivalents to
acetaminophen formation, stoichiometry experiments were conducted.

The rates of

NADPH oxidation, hydrogen consumption, product formation, H2O2, and excess water
production for phenacetin oxidation by P450 1A2 WT and mutants are shown in Table
2.2. The excess water formation was calculated from the difference between the rates of
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NADPH oxidation and rates of H2O2 and product formation (Excess H2O = NADPH –
H2O2 – product). The amount of water was also obtained from the difference between the
rate of oxygen consumption and rates of H2O2 plus product formation [H2O = 2(O2 –
H2O2 – product)], as reported by others (Fang et al., 1997), giving the values which were
very similar (within 5%) to those derived from the previous equation (data not shown).
The coincubation of phenacetin with P450 1A2 L382V and three multiple mutants,
L382V/T223N, L382V/N312L and L382V/T223N/N312L, resulted in consumption of
both NADPH and oxygen by the mutants at rates ~2-fold greater than those with the WT
enzyme. Likewise, the formation of product acetaminophen, as well as byproducts such
as H2O2 and water, were 2 to 3 times higher in the case of these mutants. The exception
was the L382V/T124S/N312L mutant, which seemed to utilize NADPH at a rate similar
to the WT enzyme, but displayed increased consumption of oxygen, along with increased
product and H2O2 formation. On the other hand, four single mutants, T124S, T223N,
V227G and N312L, are similar or less efficient than the WT with respect to NADPH
oxidation, oxygen consumption, hydrogen peroxide, and water production but exhibit a
substantial decrease in product formation.
Table 2.3 presents the effects of mutations on the coupling efficiency of P450 1A2,
both overall and at specific P450 uncoupling branching points. The ratios of product
formation to NADPH oxidation, accounting for the overall efficiency of P450 1A2
coupling of reducing equivalents to product, were higher for L382V and multiple mutants
containing the L382V substitution than for the WT. In contrast, other single mutants,
T124S, T223N, V227G and N312L, exhibited significantly decreased coupling
efficiencies compared to the WT enzyme (20-30% of WT). All of the enzymes displayed
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similar ratios of H2O2 production to O2 consumption, which suggests that the mutations
had no effect on uncoupling at the first and second branching points of the P450 cycle.
On the other hand, significant differences between the enzymes were observed with
respect to the H2O/product ratios used to measure uncoupling at the third branching point.
Thus, for the L382V mutant and multiple mutants containing the L382V substitution,
these ratios were generally lower than that for the WT, whileas for the other single
mutants, these ratios were 3-fold higher.

Therefore, low activities of the four single

mutants were likely caused by dramatically increased uncoupling to water, whereas the
increase in activity in the L382V-containing mutants resulted from decreased water
formation.

Molecular Modeling Analyses. Using the crystal structure of P450 1A2, molecular
modeling studies have been conducted to understand the effects of single and multiple
mutations on enzyme-substrate interactions and substrate mobility, as well as to explain
the alterations of catalytic efficiency.

Figure 2.1 depicts binding orientations of

phenacetin within the active sites of P450 1A2 WT and the L382V mutant. In general,
the binding orientation of phenacetin in both enzymes was very similar. However, the
replacement of Leu382 by a smaller Val increased the volume of the active site and
allowed the hydrogens at the oxidation site of phenacetin to approach closer to the ferryl
oxygen of the heme, which facilities hydrogen abstraction. The average distance between
the hydrogens at the oxidation site of phenacetin and the ferryl oxygen of the L382V
mutant was 3.1 Å, compared to 3.7 Å for the WT enzyme. Similar results were also
obtained for the L382V/T223N and L382V/T223N/N312L mutants. In contrast, both
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hydrogens at the oxidation site of phenacetin were much farther away from the ferryl
oxygen in the active sites of T124S, T223N, V227G, and N312L mutants (data no shown).
These findings correlate well with the results of kinetic and stoichiometric studies
described previously and suggest that the L382V substitution not only increases catalytic
efficiency (kcat) of P450 1A2 but also decreases Km and enzyme uncoupling.
To examine the tendency of phenacetin to remain in the productive binding
orientation in the active site of the enzyme, 100 ps of MD simulations were performed, as
described under Materials and Methods. After the 5-ps MD equilibration phase, the
energy of the system remained constant throughout the simulations. The mobility of the
substrate varied with the mutant: we observed fairly low mobility for the WT enzyme,
L382V, T124S, and L382V/T223N/N312L mutants, with root mean square deviation
(RMSD) from the initial substrate orientation of 1 to 2 Å, moderate mobility for V227L
and N312L mutants with RMSD of 2 to 4 Å, and a high phenacetin mobility in the case
of T223N and L382V/T223N mutants (RMSD >4 Å).
The productive binding orientations of phenacetin were determined using geometric
parameters, distance r and angle θ, as described under Materials and Methods. These
parameters were then plotted based on 400 recorded snapshots for each enzyme-substrate
complex. The representative plots, those for P450 1A2 WT, N312L, L382V, and
L382V/T223N mutants, showing the ensembles of substrate orientations, are presented in
Fig. 2.2. The region where the geometric criterion (r ≤ 3.5 Å and θ ≥ 120°) is satisfied is
gray, and the points (or frames) located within represent all the snapshots of each
enzyme-substrate complex where phenacetin was bound in the productive binding
orientation. The distribution of the MD frames for each enzyme-substrate complex
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displayed varied. Overall, phenacetin showed higher occupancy within a productive
binding region (counted as hits) in the L382V and L382V/T223N mutants than in the WT.
Similar results were also seen in the case of other multiple mutants containing L382V
(data not shown), whereas few hits, if any, were observed for the remaining four single
mutants, as shown for the N312L mutant (Fig. 2.2B). A quantitative analysis of the hits
for each enzyme-substrate complex revealed that the number of hits for L382V,
L382V/T223N, and L382V/T223N/N312L mutants were 2-, 4-, and 5-fold higher,
respectively, than that for the WT (Table 2.4). In contrast, zero or few hits were obtained
for T124S, T223N, V227G, and N312L mutants during 100-ps dynamics. It is possible
that some hits might be recorded during a longer simulation time. Overall, the results of
MD simulations are, like those from docking experiments, consistent with the kinetic and
stoichiometric analyses of P450 1A2 WT and mutants.
A possible drawback of the simulations described previously might have been the use
of the distance-dependent dielectric constant instead of explicit solvent. Therefore, we
have also conducted MD simulations of phenacetin docked in the active site of P450 1A2
WT and the L382V mutant with the solvent molecules present and the dielectric constant
of 1. In the presence of water, 70 hits were recorded for the WT enzyme and 144 hits for
the L382V mutant. Thus, in both cases, the percentage of hits increased less than 10%
and to a very similar extent (9.4% for the WT and 7.5% for the mutant) compared with
the results from MD simulations without water (see Table 2.4). This result indicates that,
although some changes may be observed with solvent present, simulations with distancedependent dielectric provide a reasonable approach to explain the observed experimental
findings.
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2.4 Discussion
Our previous studies indicated that residue 382 plays an important role in controlling
the specificity of alkoxyresorufin O-dealkylation by P450 1A1 and 1A2 (Liu et al., 2003;
2004; Tu et al., 2008). Because phenacetin is another important probe substrate for P450
1A2, the studies to address the effects of reciprocal mutations, particularly L382V, on
phenacetin oxidation may broaden our understanding of the role of this residue in
substrate specificity.

In the present study, nine single and multiple mutants were

investigated using a battery of complementary approaches, such as kinetic assays,
stoichiometry measurements and molecular modeling methods. The results showed that
the L382V substitution resulted in a significant increase in catalytic activity and substrate
specificity of P450 1A2. All of the multiple mutants that contained this substitution
displayed very similar kinetics, stoichiometry, and dynamic mobility as the single L382V
mutant. Thus, the presence of this single residue was critical for dramatically improving
the efficiency of phenacetin oxidation by P450 1A2.
To date, many residues of P450 1A2 have been identified that may play a role in
enzyme-ligand interactions by site-directed mutagenesis and/or molecular modeling
studies (Yun et al., 2000; Liu et al., 2004; Zhou et al., 2009). In the case of single
mutants, most of the mutations, including T124S, T223N, V227G, and N312L in the
present study, resulted in decreased catalytic activity and substrate specificity compared
to the WT enzyme (Parikh et al., 1999; Liu et al., 2004). A number of P450 1A2 mutants
obtained from random mutagenesis showed increased catalytic activities and substrate
specificities toward phenacetin (Parikh et al., 1999), but none of them was as highly
active as the L382V mutant reported in this study (Table 2.1). It is worth mentioning that
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the kinetic parameters for phenacetin O-dealkylation by P450 1A2 WT determined in the
present investigation were very similar to those reported by Parikh et al. (1999).
Although the L382V mutation dramatically increased oxidation of phenacetin, it led to a
significant decrease in 7-methoxyresorufin O-dealkylation (Liu et al., 2004). Thus, the
functional effect of residue substitution appears to be dependent on the substrate (Zhou et
al., 2009).
Moreover, the binding constants determined for P450 1A2 WT and mutants showed
that the L382V substitution leads to tighter phenacetin binding in the active site of the
L382V-containing mutants, consistent with enzyme kinetics results. This effect may
increase phenacetin residence time, resulting in higher activity.
To better explain the effects of mutations on catalytic activity and substrate specificity
of P450 1A2, stoichiometry studies were performed.

The coupling efficiencies of

different mutants, expressed in terms of product/NADPH, H2O2/O2, and H2O/product
ratios, were compared to those of WT. A similar approach has been used by Fang et al.
(1997) and Kobayashi et al. (1998) to evaluate coupling efficiencies of P450 2B1 mutants.
Frequently, the mutation decreases the coupling efficiency of the P450, as observed with
P450 2B1 (Fang et al., 1997; Kobayashi et al., 1998) and P450cam (French et al., 2002),
but the effect depends upon the substrate. Previously studied P450 1A2 mutants showed
only a small increase in coupling efficiency with phenacetin as a substrate (Yun et al.,
2000), in contrast to our results with the L382V-containing mutants. In the present
studies, the L382V mutant and multiple mutants containing the L382V substitution were
similar or more efficient at coupling reducing equivalents to acetaminophen formation
than the WT (Table 2.3). In general, the increased ratios of product/NADPH for the
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L382V mutant and multiple mutants and the decreased ratios for T124S, T223N, V227G,
and N312L mutants were in agreement with the kinetic data regarding phenacetin
turnover rates. Although no significant changes of uncoupling to H2O2 at the first and the
second branching points were observed in all the mutants, those that contained the L382V
substitution showed less uncoupling to water (decreased H2O/product ratio; Table 2.3).
Thus, it seems reasonable to suggest that the L382V substitution in P450 1A2 yields the
mutants that use NADPH and O2 more efficiently to oxidize phenacetin to products and
display less uncoupling to water, so that the overall coupling efficiency of the enzyme
increases, which is consistent with enzyme kinetics results (Table 2.1).
Molecular modeling studies provide another possible explanation of the effects of
mutations on phenacetin specificity, as indicated by changes in kinetic parameters. For
these simulations, we used the X-ray structure of P450 1A2, and the structures of the
mutants were derived from the crystal. As reported by Sansen et al. (2007), this P450
1A2 structure has a closed compact active site, without clear solvent or substrate access
channels, with a relatively small volume of the cavity, estimated at 375 Å3. The active
site of 1A2 is about 44 % larger than that of P450 2A6 (260 Å3) and significantly smaller
than that of P450 3A4 (1385 Å3) (Sansen et al., 2007). Consequently, only planar
compounds, such as α-naphthoflavone, and typical P450 1A2 substrates such as
phenacetin, 7-ethoxyresorfin, caffeine, tacrine, or theophylline can be fitted well with the
narrow and flat active site cavity of enzyme. Leu382 of P450 1A2 is a critical residue
located close to the heme iron, and its replacement with a smaller Val increases the
volume of the active site near heme. The L382V substitution allows phenacetin to move
closer to heme, so that one of the hydrogens at the oxidation site is within a hydrogen-
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bonding distance from the ferryl oxygen (Figure 2.1), which promotes hydrogen
abstraction. This is consistent with the MD results (Table 2.4, Figure 2.2). Consequently,
the movement of phenacetin closer to the ferryl oxygen in the L382V mutants helps to
explain not only the substantial increase in kcat and a decrease in Km for the production of
acetaminophen (Table 2.1) but also more efficient coupling of the P450 reaction cycle
with less water formation (Table 2.3).
MD simulations similar to those described in this work have been successfully used
in our previous studies for fairly rapid predictions or interpretation of experimental
results (Ericksen and Szklarz, 2005; Tu et al., 2008). The present studies suggest that the
use of the distance dependent dielectric constant can be a reasonable substitute for the
presence of explicit water molecules. We have observed only a small increase in the
percentage of hits (less than 10%) from MD simulations with water. These conclusions
may be further verified by more extensive MD simulations of the complete proteinsubstrate complexes on nanosecond timescales. More recently, longer 2-ns MD
simulations have been successfully used to predict the effect of mutations on the catalytic
efficiency of CYP2B6 (Nguyen et al., 2008).
In summary, our results show that the L382V substitution in P450 1A2 can alter the
binding orientation of phenacetin within the active site of the enzyme, so that the site of
metabolism moves closer to the heme iron.

This provides a good mechanistic

explanation for the increased catalytic efficiency as well as coupling efficiency of
phenacetin O-dealkylation in 1A2 mutants containing the L382V substitution.

The

current studies also show that a combination of several experimental approaches with
molecular modeling methods can improve our understanding of P450 catalysis. These
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different methodologies complement each other well to offer a mechanistic interpretation
of P450 function on a molecular level.
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Table 2.1. Kinetic Parameters for Phenacetin O-deethylation by Purified P450 1A2 WT and Mutants
Phenacetin O-deethylation
P450 1A2
kcat (/min)a

Km (μM)a

kcat/Km (Μm/min)b

[(kcat/Km)mutant/(kcat/Km)WT]

WT

1.28±0.08

59.70±1.82

0.02±0.01

1.00

T124S

0.29±0.03

28.90±1.10

0.01±0.01

0.47

T223N

0.30±0.01

26.99±0.01

0.01±0.01

0.52

V227G

0.38±0.02

32.36±2.93

0.01±0.01

0.55

N312L

0.31±0.01

25.26±0.01

0.01±0.01

0.57

L382V

3.03±0.06

5.75±0.57

0.53±0.04

24.77

L382V/T223N

3.91±0.10

7.77±0.80

0.51±0.06

23.65

L382V/N312L

3.05±0.15

16.14±2.05

0.19±0.02

8.87

L382V/T223N/N312L

3.67±0.10

32.42±11.31

0.12±0.04

5.61

L382V/T124S/N312L

2.81±0.03

10.13±2.40

0.28±0.07

13.34

a
b

Data are means of triplicate determinations.
kcat/Km represents substrate specificity.

45

Table 2.2. Rates [nmol/min/(nmol of P450)] Determined for Phenacetin Metabolism by P450 1A2 Wild-Type and Mutantsa
NADPH oxidized

O2 consumed

Product formed

H2O2 produced

Excess H2Ob

WT

43±4

22.7±0.9

1.28±0.08

14±2

15±2

T124S

27±2

14.8±0.4

0.29±0.03

10±0

9±1

T223N

41±3

17.3±0.7

0.30±0.00

10±1

14±2

V227G

40±3

16.9±0.5

0.38±0.02

9±1

15±2

N312L

32±2

18.3±0.3

0.31±0.00

13±2

10±1

L382V

84±6

47.0±1.3

3.03±0.06

29±3

30±4

L382V/T223N

98±7

57.9±2.5

3.91±0.10

38±3

32±5

L382V/N312L

70±4

41.0±2.0

3.05±0.15

29±3

18±3

L382V/T223N/N312L

72±5

41.7±1.1

2.18±0.03

28±3

23±3

L382V/T124S/N312L

42±3

34.2±0.9

3.67±0.10

26±2

9±2

P450 1A2

a

Data are means of triplicate determinations.
Excess water (H2O) was calculated from the equation: H2O= NADPH – H2O2 – product

b
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Table 2.3. Effect of Mutations on Coupling Efficiency of P450 1A2 at Different Branching Points of P450 Cyclea
Product/NADPHb

H2O2/O2c

WT

0.030

0.62

11.72

T124S

0.011

0.68

31.03

T223N

0.007

0.58

46.67

V227G

0.010

0.53

39.47

N312L

0.010

0.71

32.26

L382V

0.036

0.62

9.9

L382V/T223N

0.040

0.66

8.18

L382V/N312L

0.044

0.71

5.9

L382V/T223N/N312L

0.030

0.67

10.55

L382V/T124S/N312L

0.087

0.76

2.45

P450 1A2

a

Ratios were calculated from parameters in Table 2.2.
Efficiency of coupling reducing equivalents to product.
c
Effect on uncoupling at first or second branch point.
d
Effect on uncoupling at third branch point.
b
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H2O/Productd

Table 2.4. Geometric Analysis of MD Results for P450 1A2 WT and Mutants
Hits represent the MD frames where phenacetin was in the productive binding
orientation, as evaluated by the geometric criterion: r ≤ 3.5 Å & θ ≥ 120 ˚.

P450 1A2

Number of Hits

WT

64

T124S

0

T223N

0

V227G

4

N312L

0

L382V

134

L382V/T223N

252

L382V/T223N/N312L

308
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Figure 2.1. Binding Orientation of Phenacetin within the Active Site of P450 1A2 WT (A) and the L382V Mutant (B)
The protein backbone is depicted as a blue ribbon; the side chain of residue 382 is green, with van der Waals surface displayed; heme
is red; and phenacetin is yellow, with hydrogens at the oxidation site shown in red. The distance between the hydrogen to be
abstracted and ferryl oxygen (marked with a black line) is 3.6 Å in the WT and 2.9 Å in the L382V mutant.
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Figure 2.2. Ensembles of Substrate Orientations Obtained from 100-ps MD Simulations of Phenacetin-Enzyme Complexes,
Described by Geometric Parameters, Distance (r) and Angle (θ).
H1 in -OCH2- group of phenacetin is blue, and H2 is red. Gray regions, where the criterion (r ≤ 3.5 Å & θ ≥ 120°) is satisfied,
represent productive binding orientations of phenacetin within the active site. P450 1A2 enzymes were: WT (A), N312L mutant (B),
L382V mutant (C) and L382V/T223N mutant (D).

50

Chapter 3

Binding of Phenacetin within the Active Site of Human Cytochrome
P450 1A2 Wild Type and Mutants
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3.1 Introduction
Cytochromes P450 (P450s) are responsible for the oxidation of a large variety of
drugs, carcinogens, and other xenobiotics in species ranging from bacteria to humans. A
P450 enzyme usually has the ability to metabolize a number of different substrates, and
different P450s often display overlapping substrate specificities and inhibitor
susceptibilities (Guengerich et al., 1993).
P450 1A subfamily has two isoforms: 1A1 and 1A2. P450 1A1 and 1A2 share ~72%
sequence identity but display different substrate specificities and inhibitor susceptibilities.
P450 1A2 is a hepatic enzyme responsible for about 11% of drug metabolism in humans
(Shimada et al., 1994). P450 1A2 was first characterized as phenacetin O-dealkylase
(Distlerath et al., 1985), and phenacetin O-dealkylation has been used as the most
common marker reaction for P450 1A2 activity in the in vitro studies (Yuan et al., 2002).
Residue Leu382 in P450 1A2 is located near the heme iron and thus may play a role
in determining substrate specificity. This was confirmed by the finding that the L382V
mutation altered enzyme specificity with alkoxyresorufins and phenacetin (Liu et al.,
2004; Tu et. al., 2008; Huang and Szklarz, 2010). Enzyme kinetics studies have shown
that the L382V mutant and other multiple mutants containing the L382V mutation
displayed about 2- or 3-fold higher catalytic activities with phenacetin, than the WT
enzyme, while single mutants such as T124S, T223N, V227G, N312L and L382V showed
much lower activities (Huang and Szklarz, 2010). MD studies have shown that the
substitution of Leu by a smaller Val increased the volume of the active site, and allowed
the substrate phenacetin to move closer to the heme iron, thereby promoting hydrogen
abstraction and increasing P450 catalysis (Huang and Szklarz, 2010). However, no direct
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experimental evidence has been available so far to support this mechanism. Thus, in the
current studies, we employed NMR longitudinal (T1) relaxation measurements to
elucidate the differences in binding orientations of substrate phenacetin within the active
sites of P450 1A2 wild type and mutants. In the presence of paramagnetic molecules such
as iron, nuclear magnetic resonance (NMR)-derived T1 relaxation time is shortened in a
distance-dependent manner (Regal and Nelson, 2000; Mildvan and Gupta, 1978).
Therefore, the distance of ligand protons from the heme of cytochrome P450 can be
estimated by calculating the difference of T1 relaxation times before and after P450 is
bubbled with carbon monoxide and the T1 times of substrate protons closest to the heme
iron will show larger decreases than T1 times of those farther away (Regal and Nelson,
2000; Mildvan and Gupta, 1978).

NMR T1 relaxation measurement has been

successfully utilized to study the following ligand-P450 complexes: sodium laurate-P450
BM3, caffeine-P450 1A1, codeine-P450 2D6 and diclofenac-P450 2C9 (Regal and
Nelson, 2000; Modi et al., 1995; 1996; Poli-Scaife et al., 1997). However, T1 relaxation
measurement has not been applied as extensively as other spectroscopic technologies for
P450 research due to the requirement of large amounts of highly purified enzymes and
sufficiently water-soluble substrates.
Our previous molecular modeling studies only provided an explanation for the
possible mechanism(s) involved in the alteration of catalytic activities of mutants.
Therefore, we adopt 1H NMR T1 relaxation technique as an experimental method to
investigate the differences in binding orientation of phenacetin within the active site of
P450 1A2 WT and the mutants in order to give direct evidence to support the proposed
mechanism(s).
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This study reports the application of NMR T1 relaxation measurements to determine
the heme iron-substrate proton distance in P450 1A2 WT and the mutants. A model for
the binding orientation of phenacetin in the active sites of P450 1A2 WT and the mutants
is proposed using the constraint distances derived from NMR data. The purpose of these
studies was to gain additional information on mechanism(s) involved in altered catalytic
activities of P450 1A2 WT and some mutants.

3.2 Materials and Methods
Materials. D2O, sodium dithionite, and phenacetin were purchased from SigmaAldrich (St. Louis, MO). Potassium phosphate and EDTA were purchased from Thermo
Fisher Scientific (Waltham, MA). All other chemicals were of analytical grade and were
obtained from standard commercial sources.

Protein Expression and Purification. P450 1A2 WT, single mutants N312L and
L382V, and a multiple mutant L382V/N312L, were expressed in E. coli according to
previously established methods (Liu et al., 2004; Tu et al., 2008; Huang and Szklarz,
2010).

Binding Constant Determination. Spectral binding constants for phenacetin bound
in the active site of P450 1A2 WT and mutants were obtained as previously reported
(Huang and Szklarz, 2010). The spectrophotometer was set to record spectra from 350 to
500 nm wavelengths.

All samples contained 100 mM phosphate (pH 7.4) and the

temperature was held at a constant 27°C.
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The spectral binding constant (Ks) was

calculated using Eq. [1]
ΔA = (Bmax*S)/(Ks + S)

[1]

Spin State Shift Induced by Substrate Binding. The percentages of high and low
spin in P450 1A2 enzymes with phenacetin were determined as described previously
(Hummel et al., 2008) with some modifications. Phenacetin-induced spin state changes
with P450 1A2 WT and mutants were performed as described under Binding Constant
Determination. Spectra titrations with phenacetin in P450 1A2 enzymes were performed
with the concentrations of phenacetin used in samples identical to those used in NMR
measurements. Absorbance spectra were deconvoluted into three components: a low spin
component, a high spin component and the board δ-band by using the multiple peak
fitting package of Igor Pro 5.0 (Wavemetrics, Inc., Lake Oswego, Oregon), as described
previously for P450CAM (Jung et al., 1991), P450eryF (Roberts et al., 2006) and P450 3A4
(Roberts et al., 2005). The relative areas for high spin and low spin components were
calculated and compared to the low spin reference spectra in order to obtain percentages
of high and low spin.

T1 Relaxation Measurements. NMR T1 relaxation studies were carried out on a
Varian Spectrometer operating at 600 MHz, internally locked on the deuterium signal of
the solvent, D2O, as described previously (Hummel et al., 2008). Signals were internally
referenced to HDO peak at 4.8 ppm. A standard inversion recovery sequence (d1-180°d2-90°) was employed, along with presaturation of the residual HDO signal. The PW90
was calibrated on each sample. The preacquisition delay d1 was set to 10 x T1 (40 s) of
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the longest relaxation time. The spectra associated with at least 10 d2 values were
acquired. Line broadening and gaussian function were applied for precise calculations of
T1 values for the protons. The value of the longitudinal relaxation time was obtained by a
nonlinear least square fitting of the peak height as a function of the delay d2, using the
Varian software. T1 was measured in the initial substrate solution and after addition of
the enzyme to each substrate. No significant P420 formation was observed throughout
the course of the experiment.

T1 Temperature Dependence.

That the temperature dependence of the T1P for

phenacetin protons must behave in a temperature dependent manner is one of the
requirements for valid proton to heme distance estimates in order to confirm that the
molecules that come in contact with heme iron and those in the bulk solution are
operating under fast-exchange conditions. This can be demonstrated by conducting T1
measurements over a range of temperatures (Regal and Nelson, 2000). In this experiment,
T1 measurements were performed as described in the section on T1 Relaxation
Measurements at three different temperatures (283, 298, and 310 K). Data were collected
both in the absence (T1, Fe3+) and the presence (1/T1,Fe2+ -CO) of CO/sodium dithionite. To
ensure adequate diffusion of CO and mixing of sodium dithionite, samples were removed
from the NMR tube and placed in a test tube, CO was bubbled, and sodium dithionite was
added, and then the sample was placed back into the NMR tube. Plots of T1, Fe3+, 1/T1,Fe2+
-CO,

and 1/T1p versus 1/temperature were drawn in all cases.

Distance calculations. A more precise method for the distance (r) calculation using
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spin-state data was adopted, described in detail earlier (Hummel et al., 2008). Briefly, the
equation for distance calculation can be written as:
r = [9.78 x 1016T1P αmS(S+1)τc)]1/6

[2]

The distance is given by r. The tumbling coefficient τc represents the correlation time of
the dipolar interactions of the protein in solution and can be calculated by measuring T1P
at several magnetic field strengths (Mildvan and Gupta, 1978). An estimate for τc of
P450 1A2 is 3.38 x 10-10 s-1, as reported previously (Regal and Nelson, 2000). T1P is the
portion of T1 due to paramagnetic affects alone and is given by the following equation:
1/T1P =T1, Fe3+ - 1/T1,Fe2+ -CO

[3]

assuming that all of the diamagnetic contribution is represented by 1/T1,Fe2+ -CO (Regal
and Nelson, 2000). This assumption appears to be generally valid when used in many
similar studies (Paine et al., 1996; Poli-Scaife et al., 1997; Mock et al., 2002). The
parameter αm, the fractional binding coefficient, is obtained by the equation αm=
[P450]/(Ks+[Substrate]) under conditions of fast exchange when only one substrate is
present (Regal and Nelson, 2000). Ks values determined from visible spectroscopy were
utilized for the distance calculations rather than KD determined by NMR for phenacetin
because of the equal or slight difference between Ks and KD based on Michaelis-Menten
kinetics (Regal and Nelson, 2000). The S(S+1) term was simplified by Eq. [4]
S(S+1) = 8.75fHS + 0.75fLS

[4]

where fHS and fLS refer to the fractions of the high spin and low spin iron, respectively
(Hummel et al., 2008).

Molecular Modeling.

Molecular modeling was conducted on an SGI Octane
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workstation using the Insight II software (Accelrys, Inc). The crystal structure of P450
1A2 was obtained courtesy of Dr. Eric F. Johnson (the Scripps Research Institute, La
Jolla, CA). The mutants were constructed by the replacement of amino acid residue(s)
followed by 500 steps of steepest descent minimization. Substrate phenacetin was built
using the Builder module of Insight II. The substrate was initially placed into the active
site manually avoiding steric overlaps and docked using the Affinity module. From 20
orientations obtained, the most energetically favorable complex was subjected to MD
simulations and minimization with NMR-based distance restraints imposed. To reduce
possible protein deformation resulting from restraint forces, the protein backbone was
tethered to its initial coordinates by a harmonic restraint force. Substrate protons were
guided to suitable distances from the heme iron by a gradually strengthening harmonic
restraint (k = 2-32 kcal/mol Å) over 50 ps of MD. The nonbond cutoff was set at 15 Å,
and distance-dependent dielectric was used. Residues farther than 10 Å from the initial
substrate position were held fixed. After MD simulations, the structure was minimized
by 1000 steps of steepest descents and 1000 steps of conjugate gradients minimizations.

3.3 Results
Interactions of Phenacetin with P450 1A2 WT and the Mutants. The chemical
structure along with the proton numbering schemes used for phenacetin appears in Figure
3.1. The addition of different concentrations of phenacetin to purified P450 1A2 WT and
mutants led to an increase of their Soret peak at 390 nm and a decrease of a band at 417
nm, as shown in Figure 3.2A. Thus, for all enzymes, we observed a typical Type I
spectrum, which indicates a change of the spin state of the heme iron from low spin (S =
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1/2) to high spin (S = 5/2) due to the binding of the substrate to the protein in close
proximity of heme (Dawson, 1988). The dependence of UV absorption changes on the
concentration of substrates was used to calculate the spectral binding constants, Ks, for
the P450-phenacetin complexes at 27°C. Table 3.1 presents the Ks values obtained for
phenacetin binding, with P450 1A2 WT and the mutants, respectively. The Ks values for
N312L, L382V, L382V/N312L mutants decreased compared to the WT enzyme (Figure
3.2B).
The UV/vis spectra (wavelength 320-500 nm) of P450 1A2 WT and the mutants can
be deconvoluted into a low spin component (~416-420 nm), a high spin component
(~390-405 nm), and δ bands (~360 nm).

The concentrations of phenacetin used in the

percentage determination of spin state were identical to those used in NMR T1 studies.
The percentages of low and high spin calculated from the Soret bands of P450 1A2 WT
and the mutants in the absence and presence of substrate are shown in Table 3.2. In the
absence of substrate, P450 1A2 WT and the mutants, L312N, L382V, and L382V/N312L,
existed primarily in the low spin state (93%-97% low spin). The addition of phenacetin
increased the percentage of high spin enzyme to approximately 2- to 3-fold. It is critical
to know these relative percentages for interpreting NMR data because the increasing
concentration of high spin results in paramagnetic broadening and shifting (Bertini et al.,
2001; Pintacuda et al., 2003).

Validation of fast-exchange conditions. The validity of distances derived from T1
relaxation times of substrate protons is dependent on the substrate under fast-exchange
conditions, meaning that substrate molecules in the active site must be rapidly
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exchanging with those in the bulk solution. To verify fast-exchange conditions, the
temperature dependence of the T1 relaxation of the substrate protons is used. A positive
slope in the double reciprocal plot of T1p versus temperature indicates that the fast
exchange condition is being met. This condition also requires that double reciprocal plots
of T1, Fe3+ or T1,Fe2+ -CO versus temperature have positive slopes. The double reciprocal
plots of T1p versus temperature for P450 1A2 WT, L312N, L382V, and L382V/N312L
mutants are shown in Figure 3.3 and demonstrate that the fast exchange requirement has
been satisfied.

Calculation of Distances between Substrate Protons and Heme Iron. The average
distances between the substrate protons and the heme iron for phenacetin with each of the
enzymes, P450 1A2 WT, N312L, L382V, and L382V/N312L mutants, were obtained
from T1 relaxation experiments (Table 3.3). T1 relaxation times decreased for all protons
of phenacetin in the presence of enzymes compared to those measured in the presence of
enzymes and carbon monoxide. There is a substantial difference in T1 relaxation times
between the samples with and without carbon monoxide. All the aromatic protons of
phenacetin are nearly equidistant from the heme iron. The distance between the proton of
the –OCH2 group, which is abstracted during phenacetin oxidation, and the heme iron is
much shorter in the L382V mutant (3.73 Å) and L382V/N312L mutant (3.96 Å) than that
in WT (4.55 Å). In contrast, the distance between the proton of the –OCH2 group and the
heme iron is longer in the N312L mutant (5.84 Å) than that in WT, consistent with the
previous modeling results.

The 1H NMR spectrum of phenacetin consists of well-

resolved signals which can be easily followed during the experiment (Figure 3.4). In
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addition, the distances obtained by averaging the 20 lowest conformations of the
phenacetin are also presented in Table 3.3. The calculated distances between the protons
of phenacetin and heme iron have a good correlation with T1 data.

Position of Phenacetin Relative to the Heme of P450 1A2 Based on NMR Data and
Molecular Modeling. 3D models consisting of the substrate phenacetin and P450 1A2
and various mutants that correspond to the proton-heme distance of Table 3.3 were
constructed. The energy of substrate conformations found in those models with the
constraints of NMR-derived distances was never higher than 5 kcal/mol. Figure 3.5 only
displays the binding orientations of phenacetin within the active sites of P450 1A2 WT
and L382V mutant (P450 1A2 WT and L382V mutant are superimposed and only P450
1A2 WT is shown). Phenacetin displays similar binding orientations in both P450 1A2
WT and L382V mutant.

The protons of –OCH2 group of phenacetin, the site of

metabolism, are shown closer to the heme-iron in L382V mutant than WT. The
orientations of phenacetin within the active sites of P450 1A1 WT, 1A2 N312L and
L382V/N312L mutants are not displayed to avoid the crowded demonstration.

3.4 Discussion
The methods to study the structure-function relationships of P450s have often
involved a combination of molecular modeling and experimental techniques, such as
enzyme catalytic assays and site-directed mutagenesis (Szklarz and Halpert, 1997;
Szklarz et al., 2000). P450 1A1 and 1A2 are major members of P450 1A subfamily and
display high sequence identity. Therefore, it is of great interest to determine whether the
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substitutions of key residues of one enzyme with the residues of the other will convert the
activity for various substrates. Molecular modeling and experimental studies have shown
that single and multiple reciprocal mutants of P450 1A1 and 1A2 displayed altered
specificities toward alkoxyresorufins (Liu et al., 2004; Tu et al., 2008). Similar changes
of substrate specificities resulting from reciprocal mutations were also found in P450 2B4
and 2B5 (Szklarz et al., 1996; He et al., 1996), P450 2A6 and 2A13 (DeVore et al., 2008).
The substitution of certain P450 residue(s) by site-directed mutagenesis may change
the structure and function of P450s by affecting such events as the orientation of the
substrate in the active site, the folding of the enzyme, the electron transfer from redox
partners, or the catalytic efficiency of the enzyme through some other unknown
mechanism(s) (Hummel et al., 2008). Based on our previous molecular modeling studies,
The L382V substitution results in the substrate phenacetin closer to the oxo-heme, with
the sites of oxidation closer to the active oxygen, which might play a role in the increase
of catalytic activity (Huang and Szklarz, 2010). Other similar studies have confirmed
that the distance between heme iron and substrate protons, especially the sites of the
oxidation, correlates well with observed catalytic efficiency of the enzymes (Poli-Scaife
et al., 1997; Regal and Nelson, 2000; Hummel et al., 2008).
P450 1A2 single and multiple mutants were constructed based on the strategy of
reciprocal mutation, related to P450 1A1. Thus, the distance between phenacetin proton
and heme iron for P450 1A1 was calculated (data not shown). The substrate proton-heme
iron distances of P450 1A1 are similar as those of P450 1A2, except for the –OCH2 group.
The distance between the protons of the –OCH2 group and heme iron is larger than 6.7 Å,
which is similar to that of P450 1A2 N312L. In contrast, the sites of the oxidation for
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P450 1A2 L382V and L382V/N312L mutants display closer to the heme iron than those
of the WT enzyme (Table 3.3). Ks values for P450s suggest that phenacetin binds much
tighter to P450 1A2 L382V and L382V/N312L than to WT and N312L (Table 3.1), as
well as P450 1A1 (data not shown). Therefore, these findings provide the reasons for the
fact that P450 1A2 and mutants containing L382V substitution display increased
phenacetin O-dealkoxylation, while P450 1A1 and P450 1A2 N312L catalyze phenacetin
with a very low efficiency, as shown in our previous studies (Huang and Szklarz, 2010).
In terms of the calculating methods for the distance (r) between substrate protonsheme iron, there are two primary ways described in NMR T1 relaxation measurements.
An earlier method used the equation r = C [T1Pαmƒ(τc)]1/6, where constant C for Fe (III)
low spin is 539 , (Mildvan and Gupta, 1978). The current method takes into account the
fact that the spin state may change when the substrate binds and, therefore, the value of C
may be incorrect. To correct it, the following equation is used: r = [9.78 x 1016T1P
αmS(S+1)τc)]1/6, which is shown as Eq. [2]. T1P is not exactly the same as the T1P in the
earlier method in that it is the weighted average of individual equivalent nuclei that give
rise to the resonance. αm is calculated as in the earlier method assuming only one
substrate molecule in the binding site. The calculation of αm is more complicated if more
than one substrate is available in the active site (Hummel et al., 2008). The current
method provides a more precise calculation of the distance when spin-state data are
obtained, and it has been successfully used to calculate substrate-heme distance in P450
2C9 allelic variants with and without the presence of the heterotropic activator dapsone
(Hummel et al., 2008).
Distances derived from NMR T1 relaxation (experimental distance) represent the
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time-averaged binding orientation of phenacetin within the active site of P450 1A2 WT
and the mutants if this substrate can adopt different conformations or positions in the
active site. In this study, substrate docking and MD were also performed to obtain the
calculated distances by averaging the conformations obtained from MD (Table 3.3),
which has been described in previous P450 2C9 study (Hummel et al., 2004). The
calculated and experimental values are slight different, in part, because the distances
calculated from MD are based on a very small subset of orientations, while the distances
calculated from the T1 data represent a large number of possible orientations. Therefore,
these values should be very similar if MD run time is long enough.
In summary, the L382V substitution for P450 1A2 led to the site of metabolism of
phenacetin oriented more closely to the heme iron than in the WT enzyme. Spectral
binding studies revealed that the L382V mutation increased the affinity of the mutants for
phenacetin to a large extent.

These results demonstrate that both the distance of

phenacetin protons from the heme-iron and the alteration of substrate binding affinity are
likely responsible for the changes of enzyme catalytic efficiency, which is consistent with
our previous findings regarding enzyme kinetics and stoichiometry, as well as predictions
from molecular modeling studies (Huang and Szklarz, 2010).
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Table 3.1. Spectral Binding Constants for Phenacetin with Purified P450 1A2 WT
and the Mutants at 27 °Ca
P450 1A2

Ks (μM)

WT

17.1

N312L

10.2

L382V

0.7

L382V/N312L

3.5

a

The two cuvettes contained 0.5 μM P450 1A2 WT or the mutants in 0.1 M phosphate
buffer, pH 7.4, with 20% glycerol.
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Table 3.2. Percentages of Low Spin and High Spin in P450 1A2 WT and the
Mutants in the Absence and the Presence of Phenacetin at 27°C a
P450 1A2 (+substrate)

% Low Spin

% High Spin

WT (unbound)

93

7

WT + Phenacetin

84

16

N312L (unbound)

94

6

N312L + Phenacetin

79

21

L382V (unbound)

95

5

L382V + Phenacetin

86

14

L382V/N312L (unbound)

94

6

L382V/N312L + Phenacetin

83

17
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Table 3.3. T1 and Calculated Distances of Phenacetin Protons from the Heme Iron in the Active Site of P450 1A2 WT and the
Mutantsa.

P450 1A2 WTc

Phenacetinb

P450 1A2 L382Vd

T1, Fe3+

T1, Fe2+ -CO

rg(Å)

Rh(Å)

T1, Fe3+

T1, Fe2+ -CO

r (Å)

R(Å)

Ar 2,6

2.35 (0.18)

3.00 (0.21)

4.79 (0.33)

5.22 (1.22)

2.28 (0.11)

2.57 (0.24)

4.34 (0.26)

4.99 (0.71)

Ar 3.5

1.84 (0.10)

2.13 (0.11)

4.72 (0.14)

5.12 (1.21)

3.07 (0.22)

3.38 (0.28)

4.39 (0.31)

4.80 (0.79)

-OCH2

1.58 (0.15)

1.80 (0.18)

4.55 (0.32)

4.68 (1.26)

2.43 (0.18)

3.09 (0.17)

3.73 (0.26)

3.90 (1.52)

-COCH3

1.34 (0.07)

1.45 (0.06)

5.85 (0.13)

5.84 (2.33)

1.64 (0.13)

1.72 (0.14)

4.79 (0.23)

5.04 (2.44)

-CH3

1.44 (0.07)

1.61 (0.06)

4.69 (0.09)

4.94 (1.33)

2.03 (0.13)

2.05 (0.20)

4.13 (0.61)

4.22 (1.32)

P450 1A2 N312Le

Phenacetinb

P450 1A2 L382V/N312Lf

T1, Fe3+

T1, Fe2+ -CO

r (Å)

R(Å)

T1, Fe3+

T1, Fe2+ -CO

r (Å)

R(Å)

Ar 2,6

2.32 (0.10)

3.13 (0.15)

6.03 (0.21)

6.22 (1.23)

2.43 (0.07)

2.64 (0.19)

4.32 (0.15)

4.26 (0.99)

Ar 3.5

1.94 (0.09)

2.12 (0.11)

5.94 (0.12)

6.18 (1.21)

2.95 (0.09)

3.26 (0.11)

4.37 (0.14)

4.35 (1.21)
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-OCH2

1.62 (0.04)

1.70 (0.18)

5.84 (0.77)

5.94 (3.21)

1.98 (0.12)

2.53 (0.09)

3.96 (0.54)

4.15 (0.78)

-COCH3

1.54 (0.12)

1.98 (0.21)

6.19 (0.32)

6.73 (2.04)

2.12 (0.24)

2.43 (0.22)

4.62 (0.25)

5.00 (1.96)

-CH3

1.87 (0.12)

2.39 (0.06)

5.83 (0.36)

5.99 (1.33)

2.23 (0.23)

2.54 (0.21)

4.32 (0.23)

4.45 (1.02)

a

Errors for measurements are shown in parentheses. Errors in the T1 values were those reported by the fitting routine. Errors in the
reported distances (r) were determined by propagation of error from the T1 calculation. Generally, the error is <10 %.
b
See Fig. 1 for numbering scheme of the protons for phenacetin.
c
[P450 1A2 WT] = 0.017 μM, [phenacetin] = 171 μM, KS (P450 1A2 WT) = 17.1 μM.
d
[P450 1A2 L382V] = 0.007 μM, [phenacetin] = 7 μM, KS (P450 1A2 L382V) = 0.7 μM.
e
[P450 1A2 N312L] = 0.011 μM, [phenacetin] = 102 μM, KS (P450 1A2 N312L) = 10.2 μM.
f
[P450 1A2 L382V/N312L] = 0.004 μM, [phenacetin] = 35 μM, KS (P450 1A2 L382V/N312L) = 3.5 μM.
g
Values were calculated by r = [9.78 x 1016T1P αmS(S+1)τc)]1/6
h
Values were obtained by averaging the 20 lowest-energy conformations obtained from molecular dynamics.
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Figure 3.1. Chemical Structure of Phenacetin
Numbering scheme used in the text is shown.
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Figure 3.2. Phenacetin Spectral Binding Determined in P450 1A2 Mutants by
UV/Vis Spectroscopy
Spectral binding curves for phenacetin bound in P450 1A2 L382V. P450 1A2 WT,
N312L, L382V/N312L have a similar UV/Vis binding spectra (not shown). A type I
spectrum is evident with a peak at ~390 nm and a trough at ~420 nm. The arrows
indicate the increase of concentrations of phenacetin. (B) Binding curves for phenacetin
in P450 WT and the L382V mutant and the KS values derived from fitting of the data to
Eq. [1].
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Figure 3.3. Temperature Dependence of the Longitudinal Relaxation Time of the NMR Resonances of Phenacetin Protons in
P450 1A2 WT and Mutants
The plots present P450 1A2 WT (A), N312L (B), L382V (C) and L382V/N312L mutants (D), respectively. A positive linear slope is
indicative of fast-exchange conditions. Legend: Phenacetin Ar 2,6 (●), Ar 3,5 (○), -CH2 (▲), -COCH3 (△), and –CH3 (■).
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Figure 3.4. NMR Spectrum of the Protons of Phenacetin Obtained under Conditions Used for T1 Measurements
The numbering scheme used is the same as shown in Figure 3.1.
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Figure 3.5. Phenacetin Binding Orientation in the Active Site of P450 1A2 WT
(yellow) and the L382V Mutant (green).
The enzymes were superimposed using a protein backbone as a basis. Optimal
orientations for the docked substrate were refined by incorporating NMR-derived
distance restraints. The substrate adopts very similar binding positions in both enzymes.

73

Chapter 4

Application of Molecular Modeling to Study Cytochrome P450 1A2
Inhibition by Various Selective Inhibitors
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4.1 Introduction
Cytochromes P450 (P450s) are unique monoxygenases, which are found in every
biological kingdom and almost every tissue in mammals (Nelson et al., 1996). Most
P450s detoxify xenobiotics by forming hydrophilic metabolites which can be readily
excreted from the body. However, P450s also play an important role in activating procarcinogens and other toxic compounds (Ortiz de Montellano, 1996). In general, the
catalytic mechanism involves a two-electron reduction of molecular oxygen to form a
reactive oxygen species able to oxidize a substrate, and water (Porter and Coon, 1991).
P450 1A2, which is a member of P450 1A subfamily, is one of the major hepatic
enzymes in human beings, and accounts for about 13% of the total cytochrome P450
content of human liver microsomes (Faber et al., 2005). P450 1A2 is responsible for the
metabolism of a large number of compounds of both exogenous and endogenous origin,
such as theophylline, caffeine, imipramine, acetaminophen, and propranolol as well as
17-estradiol and uroporphyrinogen III (Brøsen K., 1995; Guengerich FP and Shimada T.,
1991). In addition, P450 1A2 is of particular importance in carcinogenesis due to its
activation of heterocyclic amines that are present in cooked meat and fish (Turesky et al.,
1996).

These amines are converted to hydroxyamino derivatives, which ultimately

produce DNA adducts (Yamashita et al., 1988). Thus, high levels of P450 1A2 could
enhance an individual’s susceptibility to carcinogenesis and modulation of P450 1A2
activity by selective inhibitors could have important implications for cancer prevention
(Chohan et al., 2005).
Moreover, P450 1A2 inhibition may explain some drug-drug interactions in patients.
A good example is fluvoxamine, a potent P450 1A2 selective inhibitor, which increased
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the plasma concentrations of caffeine when coadministered with this compound,
indicating that the intake of caffeine during fluvoxamine treatment may lead to caffeine
intoxication (Jeppesen et al., 1996).
At this time, many P450 1A2 selective inhibitors have been identified.

The

fluoroquinolone ciprofloxacin (Fuhr et al., 1992), the antidepressant fluvoxamine (Brøsen
et al., 1993) and methylxanthine furafylline (Kunze and Trager, 1993) have been used as
model inhibitors of P450 1A2. However, till now, little data have been available on the
mechanism(s) of inhibitor binding, which hampered further determination of biological
roles and structure-based design of potent and selective inhibitors.
In order to study the function of P450 1A2, a number of homology models (Dai et al.,
1998; Liu et al., 2004; Cho et al., 2003) were built based on mammalian P450 templates
before human P450 1A2 crystal structure in complex with α-naphthoflavone was solved
by Sansen et al. (Sansen et al., 2007). The structure has been described previously in
Chapter 1. Briefly, P450 1A2 has a relatively narrow, flat active site due to several
surrounding aromatic residues, which determines that its substrates and inhibitors are
usually small lipophilic and planar molecules (Korhonen et al., 2005).

P450 1A2

structure provides a useful template to study structure-function relationships of 1A2 with
alternative substrates and inhibitors.
To introduce inhibitors into the active site of P450 model, docking programs were
utilized to study the possible interactions and binding energies in inhibitor-enzyme
complexes. Docking programs include rigid docking programs and flexible docking
programs.

Rigid docking programs such as Autodock (http://autodock.scripps.edu/),

DOCK, FlexX, GOLD and ICM are suites of automated docking tools allowing for full
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ligand flexibility and limited flexibility for the receiptor.

AutoDock is the most

commonly cited docking program in the scientific literature (Sousa et al., 2006).
AutoDock 4.2v has a free-energy scoring function based on a linear regression analysis,
the AMBER force field, and a large set of diverse protein-ligand complexes with known
inhibition constants. Flexible docking programs, such as Affinity docking (Insight II),
perform flexible ligand docking in flexible receptor. In general, rigid docking is very fast,
while high-quality flexible docking takes much longer. Additional methods, such as MD,
and evaluation of enzyme-inhibitor interaction energies provide us with more information
on P450 catalysis and the motion of the inhibitor in the active site.
The aim of the present study was to reveal the possible mechanism(s) involved in the
interaction between the inhibitors and P450 1A2. First, we docked furafylline in the
active site of P450 1A2 WT as well as single mutants. MD simulations were then
conducted to investigate possible interaction(s) between the inhibitor and enzymes and
the altered inhibition caused by the mutations of the WT enzyme.

Secondly, we

described the use of structure-based in silico approach to evaluate the relationship
between the docking score and inhibitory effects (Ki) of both competitive and
mechanism-based inhibitors of P450 1A2 using AutoDock program.

4.2 Materials and Methods
Affinity Docking and MD Simulations. Molecular modeling was performed on SGI
workstation with Insight II software (Accelrys, Inc) using consistent valence force field
(CVFF) supplemented with parameters for heme and ferryl oxygen. The crystal structure
of P450 1A2 (Protein Data Bank: 2hi4) represented WT enzyme and served as a basis to
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construct single mutants, including T124S, T223N, V227G, N312L, L382V and F226L,
as described previously (Liu et al., 2004; Tu et al., 2008). Furafylline was built and
energy optimized using the Insight II/Builder module. Initially, this ligand was placed
manually into the active site of P450 1A2 WT or six single mutants in order to avoid
steric overlaps, and then affinity docking was performed using the Insight II/Affinity
module. Out of 20 final orientations, the most energetically favorable complex leading to
inhibitor oxidation was subjected to 5 ps MD simulations with distance restraints
imposed to obtain the optimal enzyme-inhibitor complex. The distance between the
ferryl oxygen and hydrogens at the oxidation site of furafylline was constrained to 2.753.25 Å. After the MD run, the structure was minimized with 500 steps of steepest
descents and 500 steps of conjugate gradients minimizations. Inhibitor mobility was then
investigated by 100 ps MD simulations with no restraints and the MD frames were saved
every 500 fs for further analysis. Both the inhibitor and active site residues within 15 Å
from the inhibitor were allowed to move during MD simulations.

Docking and Binding Energy Calculation Using AutoDock. Docking of several
selective P450 1A2 inhibitors, including competitive and mechanism-based inhibitors,
was performed with AutoDock 3.0v. The P450 1A2 crystal structure was used for
docking, and the docking procedure was conducted using the standard protocol. The
auxiliary program AutoGrid generated the grid maps. The grids (one for each atom type
in the inhibitors, plus one for electrostatic interactions) were chosen to be sufficiently
large to include significant portions of the active site of P450 1A2. The grid dimensions
were thus 60 × 60 × 60 Å3, with points separated by 0.375 Å. Docking was carried out
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using the empirical free energy function and the Lamarckian algorithm. The number of
docking runs was 100 and, after docking, the 50 solutions were clustered into groups with
the RMS deviations lower than 0.5 Å. The clusters were ranked by the lowest-energy
representative of each bunch.

4.3 Results
Furafylline Docking. Furafylline was docked within the active sites of P450 1A2
WT and mutants using Affinity docking program. MD simulations were then conducted
to observe the binding orientation and the mobility of furafylline. Figure 4.1 displays the
binding orientation of furafylline in the active site of P450 1A2 WT and the location of
six residues of interest, namely Thr124, Thr223, Phe226, Val227, Asn312, and Leu382 in
P450 1A2 WT, five of which have been reported to determine the specificity of P450 1A2
toward alkoxyresorufin (Liu et al., 2004). These six residues are located on the surface of
the active site cavity and are in direct contact with furafylline. The mutation of these
residues might change the binding orientation of furafylline, thereby altering the
susceptibility of the mutant enzymes to inhibition by this compound. As shown in Figure
4.1, Phe226 and furafylline might have π-π stacking interactions, which play a pivotal
role in stabilizing the binding orientation of furafylline in the active site of P450 1A2.
Therefore, MD simulations were performed to predict the effect of the mutation of
several residues on the mobility of furafylline. Thr124, Thr223, Val227, Asn312, and
Leu382 were replaced by the residues found at the equivalent locations in P450 1A1, that
is Ser122, Asn221, Gly225, Leu312, and Val382, respectively. Phe226 was replaced by
Leu, which does not have phenol group, in order to investigate the role of π-π stacking
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interactions in determining the binding orientation of furafylline in the active site of P450
1A2.

The plots of the distance (r) between the hydrogens at the oxidation site of

furafylline and the ferryl oxygen vs. simulation times are shown in Figure 4.2 for P450
1A2 WT, T124S, F226L and L382V. The distance (r) did not change for T124S and
L382V mutants, as well as T223N, V227G, N312L mutant (data not shown), compared
with the WT enzyme. Interestingly, the distance (r) showed a significant increase when
Phe226 was replaced by Leu, suggesting a decreased inhibitory effect of furafylline on
the enzyme. Figure 4.3 shows the distance (r) for the MD frames collected during the
100ps MD simulation for P450 1A2 WT and mutants. P450 1A2 T124S and L382V
displayed very similar mobility as P450 WT, in contrast to the F226L mutant, in which
furafylline moved further away from the heme iron.

P450 1A2 Affinities of Various Inhibitors.

Various potent selective inhibitors,

including eight competitive inhibitors and ten mechanism-based inhibitors, could be
successfully docked into the active site of P450 1A2. The values of docking scores (dock
energy) range from -11.83 to -9.5 kcal/mol (Figure 4.4). In general, the more negative
the value, the tighter the binding. The docking score values for these 18 inhibitors
correlate well with the experimental Ki values, with r2=0.72 for eight competitive
inhibitors and two mechanism-based inhibitors NPS100524 and furafylline; r2=0.96 for
eight mechanism-based inhibitors. Surprisingly, the data for NPS100524 and furafylline
fits well with those for competitive inhibitors instead of mechanism-based inhibitors.

4.4 Discussion
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Cytochrome P450 1A2 selective inhibitors play a key role in the prevention of P450
1A2-mediated toxic metabolite formation. Therefore, the elucidation of the molecular
mechanism of enzyme inactivation would give some insight into P450-linked
carcinogenesis and have important implications for the rational design of anticancer
drugs. In the current studies, we have studied the interactions between P450 1A2 and its
selective inhibitors in silico using the newly crystallized P450 1A2 structure. Docking of
inhibitors into the active site of the enzyme model can help to explain enzyme-inhibitor
interactions as well as the role of certain residues in catalysis (Szklarz and Halpert, 1998).
In this study, we chose two different docking programs to meet our aims. Furafyline
docking within the active site of P450 1A2 WT and mutants using Affinity docking
program provided us with more accurate information although the simulations took
longer. Therefore, to dock eighteen inhibitors, we adopted Autodock 3.0v, which is able
to quickly calculate the docking scores for those compounds (about 2 hours for each
compound). The choice of the orientation of the inhibitor bound in the active site and
corresponding docking score is important.
Docking and MD simulation studies indicated that the inhibition of furafylline does
not change in P450 1A2 T124S, T223N, V227G, N312L and L382V mutants, compared
to the WT enzyme, which has been confirmed by inhibition assays (data not shown). In
contrast, the replacement of Phe-226 with Leu led to a significant increase in the ferryl
oxygen-hydrogen distance, suggesting that the mutant becomes resistant to inactivation,
probably due to the loss of π-π stacking interactions with Phe which stabilize the
productive binding orientation of furafylline.

This prediction needs to be verified

experimentally in the future. Similarly, hydrogen bonding, π-π stacking or a combination

81

of the two plays a role in the interactions between P450 2C subfamily enzymes and their
selective inhibitors (Lewis et al., 2006).
P450 1A2 selective inhibitors were divided into two groups for docking based on the
mechanisms of the inhibition. The set of mechanism-based inhibitors displayed very
poor correlation between the docking score and Ki values (r2=0.54). In the plot of
mechanism-based inhibitors, the points for NPS100524 and furafylline are far away from
the correlation line. Surprisingly, they fitted very well with the correlation equation of
competitive inhibitors. The reasons might lie in the different mechanisms involved in the
fate of their reactive metabolites, such as reacting with amino acids present in the active
site, reacting with the porphyrinnitrogen atoms or even coordinating to the iron to form a
tight bond (Murray, 1997), which led to significant differences in docking scores.
In conclusion, we demonstrated the π-π stacking interactions might be primarily
involved in furafylline binding in the active site of P450 1A2. Other reciprocal 1A2
mutants, such as T124S, T223N, V227G, N312L and L382V did not alter their
susceptibility to inhibition by furafylline with enzymes. Using AutoDock program, good
correlations between docking score and experimental Ki were obtained for competitive
and mechanism-based inhibitors of P450 1A2. Knowledge of the interactions between
the inhibitors and the enzymes may provide deep insights for the future design of potent
selective inhibitors.
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Figure 4.1. Binding Orientation of Furafylline within the Active Site of P450 1A2
Crystal Structure
The protein backbone is depicted as cyan ribbons, the side chains of residues of interest
(within 3 Å distance from furaffyline) are pink, heme is red, and furafylline is colored by
atom type.
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Figure 4.2.
simulations

The Distance (r) Changes as a Function of Time during 100 ps MD

The r presents the distance between the ferryl oxygen and hydrogens at the oxidation site
of furafylline bound in the active site of the P450 1A2 WT, F226L, T124S, and L382V
mutants. The ideal distance leading to the reaction is 2.75 – 3.25 Å.
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The inhibitor was bound in the active site of the P450 1A2 wide type and four selected single mutants. The replacement of Phe226
with Leu led to a significant increase in the ferryl oxygen-hydrogen distance, suggesting that the mutant becomes resistant to
inactivation.
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Chapter 5

Summary and Conclusions
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We have investigated substrate specificity and inhibitor susceptibility to reveal the
structure-function relationships of P450 1A2. A combination of computational
approaches such as ligand docking and molecular dynamics simulations, and
experimental techniques such as kinetic assays, site-directed mutagenesis and
stoichiometry, were utilized to give us a better understanding of the mechanism(s)
involved in ligand-enzyme interactions.
In Chapter 2, we explored the roles of five key residues in SRS regions of P450 1A2,
namely Thr124, Thr223, Val227, Asn312, and Leu382, in determining the enzyme
specificity using phenacetin as a probe substrate. Surprisingly, catalytic assays indicated
that the of L382V substitution significantly increased the catalytic efficiency of P450
1A2 enzyme toward phenacetin O-deethylation while other four single mutations lowered
catalytic efficiency of the enzyme. In addition, stoichiometry analysis revealed that less
water formation during the P450 catalytic cycle contributed to the increased catalytic
efficiency of P450 1A2 L382V and multiple mutants containing the of L382V
substitution, compared with 1A2 WT. We then used molecular modeling to study the
mobility of phenacetin within the active sites of P450 1A2 WT and single and multiple
mutants. MD simulations suggested that the L382V substitution provides more space for
phenacetin and enable it to move closer to the heme iron, which promotes substrate
oxidation.

Thus, molecular modeling study provided a rationale to explain the higher

catalytic efficiencies of the enzymes containing L382V substitution.
Although the results of molecular modeling were consistent with enzymatic assays,
direct experimental evidences were still needed to confirm the mechanism proposed from
molecular modeling study. Therefore, NMR T1 relaxation time measurements were
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utilized as described in Chapter 3 to extend our studies on the binding orientation of
phenacetin within the active sites of P450 1A2 WT and mutants. By comparing the
distances between the protons of substrate phenacetin and the ferryl oxygen of the heme,
we concluded that the distances between the site of metabolism of phenacetin and the
oxo-heme of P450 L382V and mutants containing the of L382V substitution are
significantly shorter than those of P450 1A2 WT and N312L as well as P450 1A1 WT.
Thus, NMR measurements provide concrete evidence to explain the increased catalytic
efficiencies of the enzymes.
In Chapter 4, we used selective inhibitors as another type of ligand to investigate their
interactions with P450 1A2 WT and mutants. Furafylline docking and site-directed
mutagenesis suggested that π-π stacking might play a role in stabilizing the binding
orientation of furafylline within the active site of P450 1A2. No hydrogen bonds were
found in the interaction between furafylline and P450 1A2. The inhibitory potential of
an inhibitor correlated well with the binding score. The stronger the inhibitor, the higher
the binding interaction with the enzyme.
Taken together, we have tried to use computational approaches and experimental
techniques to elucidate the mechanism(s) involved in determining the substrate
specificity and inhibitor susceptibility of P450 1A2.

A better understanding of the

catalytic mechanism, substrate binding and turnover, the mechanism(s) of P450 inhibition,
as well as the structural basis for enzyme function, would give us some insight into P450linked carcinogenesis and have important implications for the rational design of
anticancer drugs.
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